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Cyclic adenosine monophosphate (cAMP) is a ubiquitous second messenger that regulates 
cellular proliferation, differentiation, attachment, migration, and several other processes.  It has 
become increasingly evident that tight regulation of cAMP accumulation and localization confers 
divergent yet specific signaling to pathways downstream. Currently, few tools are available with 
sufficient spatial and temporal resolution to study location-biased cAMP signaling. Here, we 
introduce a new fusion protein consisting of a light-activated cyclase (bPAC) and luciferase 
(nLuc). This novel construct allows dual activation of cAMP production using temporally 
precise photostimulation or chronic chemical stimulation. Furthermore, we directed this 
construct to various subcellular compartments to improve spatial resolution. Using a combination 
of FRET imaging and optogenetics, we investigate location-biased signaling in thyroid epithelial 
mitogenesis and potential applications of bPAC-nLuc in vivo. A better understanding of the 
physical interactions and dynamics between cAMP and multiple signaling pathways may provide 
new therapeutic approaches for treating diseases with aberrant cAMP signaling. 
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PREFACE 
The phrase popularized by Isaac Newton, “If I have seen further it is by standing on the 
shoulders of Giants,” encapsulates my view as a scientist, particularly after learning the history 
of the idiom. Most reiterations of this hackneyed phrase exclude the original metaphor by 
Bernard of Chartres, “We are like dwarfs sitting on the shoulders of giants. We see more, and 
things that are more distant, than they did, not because our sight is superior or because we are 
taller than they, but because they raise us up, and by their great stature add to ours.” I find this 
reminder that we are humbly smaller in perspective compared to the grand body of literature 
supporting biomedical research. We strive to bring the universe in our heads into something our 
hands can grasp through innovative and sometimes clumsy ways. We do not aim to be giants; we 
just want to see a little further. This metaphor suggests that over time some dwarfs become 
giants, but I think this is a mistake in perspective. The ‘giants’ we see are an amalgamation of 
many dwarfs who have worked as we have. Thus, I would like to thank my fellow dwarfs who 
worked with me, provided support and guidance, and helped me see farther. 
Dr. Daniel Altschuler and my lab colleagues have been instrumental in carrying out this 
work and helping me gain independence as a scientist. Jeff Reece developed the Arduino system 
from scratch and provided excellent training. My committee members continually provide 
insight into shaping experimental approaches. The Molecular Pharmacology Training Program 
and Department of Pharmacology have provided ample support and opportunities for developing 
xiii 
my career. I would like to thank my many collaborators and professors who supported this 
research: Dr. Adriana Larregina and Olga Tkacheva of the Department of Dermatology for 
teaching methodology and sharing resources for the mouse melanoma metastasis model; Dr. Jian 
Yu and Nathan Yates of the Department of Developmental Biology for teaching methodology 
and sharing resources for the ultrasound guided microinjection mouse model; Dr. Jean-Pierre 
Vilardaga and Alex White for conducting FRET experiments in the HEK293 cell model and 
sharing resources; Dr. Simon Watkins for aid in imaging in EdU-based proliferation assays; and 
Dr. Davide Calebiro of the University of Würzburg for expanding my training. Furthermore, I 
would like to thank Dr. Kees Jalink (Netherland Cancer Institue) for providing the H208 sensor, 
Dr. Walter Storkus (University of Pittsburgh) for providing the B16-F10 cell line, and Dr. Hak 
Soo Choi (Harvard Medical School) for providing the T800-F. 
Lastly, I would like to thank my favorite dwarfs who stood with me, even on low ground. 
My husband, Ethan, is the tallest dwarf I know and thus provides the greatest support I could 
have ever asked for. My parents, sisters, Sifu, friends, and the Fair People of Heidiland have 
brought me light, laughter, and countless memories which I cherish. Together you make tall. 
Work from this thesis surrounding the development of the luminescence-activated 
cyclase has been submitted for publication at this time. 
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1.0  INTRODUCTION 
Since the discovery of cyclic adenosine monophosphate (cAMP) over 60 years ago, it has been 
regarded as a critical molecule in basic cell function and human disease (1). cAMP is a key 
signaling node for multiple pathways including proliferation, differentiation, attachment, and 
migration. The initial discovery spurred a cascade of breakthroughs such as the isolation of 
cAMP-dependent protein kinase A (PKA), which formed the major biomedical field of protein 
phosphorylation (2,3). It filled major gaps in knowledge in G Protein Coupled Receptors 
(GPCRs) signaling (4-9). Additionally, cAMP regulation was vital to understanding hormone-
mediated glycogen metabolism (3). As of now, seven Nobel prizes have been awarded for 
studies directly tied to cAMP signaling. However, even with a robust history of research, the 
field still lacks an understanding of how cAMP can activate specific downstream pathways. 
Fundamental knowledge of cAMP signaling and regulation reaches across disciplines and thus 
remains essential for biomedical advancement. 
One key example that illustrates our gaps in understanding cAMP pathway specificity 
came early after its discovery. Researchers found cAMP negatively regulated proliferation in 
lymphocytes, fibroblasts, and several other mammalian cells (10,11). Hence it became a widely 
accepted dogma that cAMP was an inhibitor of proliferation. However, other groups found 
cAMP stimulated proliferation in non-dividing lymphocytes and thymocytes (12,13). Since then, 
multiple cell types have been added to each side and contradicting roles of cAMP have also been 
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found in other cells processes. This discrepancy demonstrates that the context of cAMP signaling 
is key to determining downstream effects. Cumulating literatures reveals the stimulus (14-16), 
cell type (17-21), and disease state of a cell can alter the outcome of cAMP signaling (22).  To 
distinguish the effects of cAMP, careful attention must be given to the conditions of the cell and 
environment. The regulatory machinery and kinetics of cAMP itself will be reviewed in this 
section. 
1.1 cAMP REGULATORY PROTEINS 
1.1.1 GPCR and Gαs Signaling 
cAMP synthesis is canonically stimulated by G-protein coupled receptor (GPCR) signaling. 
GPCRs are a class of transmembrane proteins with 7 membrane-spanning helices that transduce 
extracellular signals to intracellular actions. Upon binding to a ligand at its N-terminus, the 
receptor undergoes a conformational shift that stabilizes its interaction with the coupled 
heterotrimeric G protein (23). Activation of the G protein prompts exchange of GDP for GTP 
and dissociation of the Gα GTPase subunit from the Gβγ dimer (24). Of the four Gα protein 
subclasses, two regulate adenylyl cyclases (ACs) (25). Gαs stimulates AC whereas Gαi inhibits 
it. While Gαi can inhibit a few cyclase isoforms, Gαs can stimulate all nine isoforms of 
transmembrane AC (26). GPCR signaling is regulated by receptor endocytosis. Most activated 
GPCRs bind the scaffolding protein β-arrestin which sterically blocks G protein interactions and 
couples the receptor to the endocytotic machinery (27). 
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1.1.2 Adenylyl Cyclase 
Transmembrane ACs exist as dimers with 12 membrane-spanning helices and two cytoplasmic 
domains, C1 and C2, which form the catalytic pocket for converting ATP into pyrophosphate 
and cAMP (28,29). GTP-bound Gαs activates cyclase through allosteric modulation of the active 
site (30). Additionally, the pharmacologic agent forskolin can activate cyclase isoforms 1-8 alone 
or with Gαs in a synergistic or additive manner (31). Canonical activation occurs at the 
membrane, but sustained cyclase activation and signaling can occur from endosomes following 
the activation and internalization of the GPCR (32-35). Endosomal generated cAMP has been 
shown to elicit distinct effects from membrane generated cAMP (36).  
Another source of cAMP production is soluble AC (sAC or sAC10). As the name 
implies, this isoform lacks transmembrane domains and can be found throughout the cytosol. 
sAC is a ~187 kDa dimer containing C1 and C2 catalytic domains similar to transmembrane 
cyclases (37). However, unlike the transmembrane isoforms it does not respond to Gαs or 
forskolin; instead, it is activated by Ca+2 and bicarbonate (37,38). sAC is unique in that it is the 
only isoform that can produce cAMP in non-membrane regions. It has been shown to localize to 
the cytosol, nucleus, mitochondria, and sub-membrane regions (39-46). While GPCRs classically 
stimulate transmembrane cyclases, some have shown GPCRs can activate sAC indirectly through 
Ca+2 release from the endoplasmic reticulum (47).  
Individual cyclase isoforms have been linked to distinct physiological responses. For 
example, learning and memory (48-51), cardiac myocyte function (52), and olfaction (53) have 
been linked to specific AC isoforms (54). Some isoforms have been found to localize proximal to 
specific GPCRs or associate with lipid rafts, suggesting a potential mechanism for how GPCR 
signaling can activate individual isoforms (55,56). For example, in cardiac myocytes β1-
4 
adrenergic GPCRs are enriched in caveolae-lipid rafts with AC6; however, the GPCR 
prostaglandin E2 that localizes in non-raft regions of the membrane does not activate cyclase 6 
(57,58). In sum, multiple sources of cAMP reside throughout the cell and AC isoform 
localization can overlap with specific proteins and protein complexes. 
1.1.3 cAMP-dependent Protein Kinase A 
Once cAMP is synthesized, cAMP can activate a handful of effector proteins which ultimately 
lead to a wide array of physiological responses. The first effector identified was cAMP-
dependent protein kinase A (PKA), a tetrameric protein consisting of two regulatory subunits and 
two catalytic subunits (2,59). Binding to four molecules of cAMP triggers dissociation of the 
catalytic subunits which can then phosphorylate serine/threonine substrates (60). Recently a 
combination approach using CRISPR-Cas9 genome editing and large-scale mass spectrometry 
identified 229 PKA target proteins in mouse kidney epithelial cells (61), demonstrating the 
enormous number of pathways that PKA affects. 
The first mention of PKA compartmentalization was in the late 1970s when Corbin et al. 
(62) identified particulate-bound PKA and cAMP. They noted this localization was advantageous
for signaling since it placed the cAMP effector protein near the site of synthesis. Furthermore, 
after activation at the membrane, the dissociated PKA catalytic domains served as the “mobile” 
units for activating downstream cytoplasmic proteins rather than cAMP diffusion activating 
distant PKA. Later, the group of Brunton, Hayes, and Mayer elegantly demonstrated differential 
activation of PKA in the cytoplasm and sub-plasma membrane region through two different 
GPCR pathways. They found stimulating prostaglandin E1 increased PKA activation in soluble 
fractions. However, stimulation of the β-adrenergic receptor, which also elevated cAMP, 
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increased PKA activation in both soluble and particulate fractions. Furthermore, despite similar 
levels of cAMP, only β-adrenergic signaling activated glycogen phosphorylase (14,15,63-65). 
The concept of PKA pools and potential spatial distinction of cAMP activation is still being 
investigated today.  
PKA compartmentalization or its presence in signalosomes is governed by associated 
scaffolding proteins. PKA localization depends on which A Kinase Anchoring Protein (AKAP) it 
binds. AKAPs are a diverse family of proteins that has little sequence similarity and are only 
united by one feature: a 14-18 residue amphipathic helix that binds to the PKA regulatory 
subunit dimer (66,67). They contain several docking sites, each with a unique set of binding 
partners such as phosphatases, kinases, small GTPases, guanine exchange factors, 
phosphodiesterases, membrane receptors, and ion channels (68). Furthermore, AKAPs can adapt 
multiple conformational states that alter which proteins they bind (69). AKAPs have been found 
in several compartments including the membrane, nucleus, mitochondria, cytoskeleton, and 
centrosomes (70) to create dynamic cAMP-sensitive signalosomes throughout the cell. Since 
PKA can phosphorylate numerous proteins, AKAPs regulate pathway specificity by positioning 
PKA substrates and cAMP regulatory machinery to foster preferential activation (71). 
Interestingly, PKA can inhibit its own activation and reduce cAMP levels by blocking AC 
activation and activating PDEs, both of which are believed to be regulated by AKAP interactions 
(68,72-74). 
1.1.4 Exchange Protein Directly Activated by cAMP 
Another major cAMP effector protein is Exchange Protein Directly Activated by cAMP (EPAC). 
Its discovery 20 years ago identified it as a guanine nucleotide exchange factor (GEF) for the 
6 
Rap1 GTPase (75,76). GEFs facilitate GDP dissociation from inactive GTPases, allowing GTP 
to bind and form an active complex. The C-terminus of EPAC contains a catalytic CDC25-
homology domain that is stabilized by the Ras-Exchange Motif domain and Ras-association 
domain (77). The autoinhibitory N-terminal regulatory region of EPAC contains a cAMP 
binding domain (CBD), a membrane-anchoring DEP (Disheveled-Egl-10-Pleckstrin) domain, 
and an EBD domain (ERM-Binding Domain) (78,79). EPAC has been found to activate multiple 
proteins including Ras, Rho GTPases, and phospholipase C-ε (80). 
The EPAC1 isoform has been identified at the plasma membrane, cytosol, nuclear 
envelope, and mitochondria (81). EPAC1 localization at the membrane has been described by 
two different mechanisms which require an intact DEP domain. Studies suggest activated 
EPAC1 can bind to the membrane directly by interacting with phosphatidic acid (82). EPAC1 
can also directly bind to ERM (Ezrin, Radixin, Moesin) cytoskeletal scaffolding proteins, which 
recruit EPAC to the membrane (79,83). Interestingly, phosphatidic acid bound EPAC exhibits 
even expression along the membrane whereas ERM-associated EPAC forms clusters along the 
membrane (83). EPAC localization at the nuclear envelope depends on interaction of EPAC1’s 
Ras-association domain which can interact with Ran, a small GTPase that regulates nuclear 
transport (84). Although more recent studies suggest RabBP2 anchorage of EPAC1 is 
independent of Ran (83,85). These examples demonstrate spatial regulation of EPAC is critical 
for its function. 
1.1.5 Phosphodiesterase 
cAMP is rapidly degraded by phosphodiesterases (PDEs). These enzymes play a major role in 
shaping the duration of cAMP signaling. PDEs catalyze hydrolysis of the 3’ phosphate bond of 
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cAMP and cyclic guanine monophosphate (cGMP) into 5’-AMP and 5’-GMP, respectively. 
There are 11 PDE families that of which PDE 1, 3, 4, 7, 8, and 10 preferentially bind cAMP over 
cGMP (86). Only PDE 4, 7, and 8 are cAMP specific. PDE isoforms demonstrate differential 
tissue expression as well as distinct localization patterns in cells. For example, PDE8B1 is only 
expressed in the thyroid and can be found in cytosolic and particulate fractions, while PDE4A is 
widely expressed throughout the body and can localize in membrane ruffles and bind to 
scaffolding proteins such as β-arrestin and AKAPs (86). PDE isoforms can have different 
affinities for cAMP, with some having high affinities in the 10-100 nM range (PDE3 and PDE8) 
and some having low affinities for cAMP >10 μM (PDE1A and PDE2) (86,87). 
Figure 1. GPCR-mediated cAMP signaling. 
Upon binding to its ligand, GPCRs activate heterotrimeric G proteins which exchange GDP for GTP. The 
heterodimer dissociates, and the active Gαs subunit stimulates adenylyl cyclase production of cAMP. cAMP 
activates a handful of effectors including PKA, EPAC, and cyclic nucleotide gated channels (CNGs). 
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1.2 cAMP COMPARTMENTALIZATION PARADIGM 
The combination of ACs, PDEs, effector proteins, and scaffolding proteins that regulate cAMP 
signaling result in three temporal patterns of accumulation: transient, sustained, and oscillating. 
GPCR endocytosis, PKA-driven negative feedback loops, and PDE activity result in transient 
spikes of cAMP production (88-91). Several GPCRs exhibit sustained cAMP production 
(32,33,92-95) and activating mutations in the GPCR pathway can lead to constitutive production 
of cAMP (96-99). Additionally, cAMP oscillations have been reported in pancreatic β cells 
(100,101), neurons (102,103), pituitary cells (104), and in myocardiac cells (105). In addition to 
this temporal regulation, spatial regulation was also demonstrated by differential cyclase 
localization and AKAP signalosomes. Although proximity-based signaling mechanisms may 
accelerate protein-protein interactions, the characteristics of the small molecule cAMP pose a 
problem for location-dependent models given the classic paradigm of diffusion. 
1.2.1 Problems with Previous Models of cAMP Diffusion 
The first studies measuring cAMP diffusion rates in cells measured a diffusion coefficient  of ~3 
x 10-6 cm2/s (106,107) which was similar to values obtained in aqueous solutions (108). These 
measurements were taken in amphibian olfactory cilia and cAMP concentrations were measured 
via voltage changes from cyclic nucleotide-gated channels (CNGs). Chen et. al. performed their 
studies in the absence of PDE activity and noted that higher levels of cAMP (5 μM) diffused 
more slowly (107). Thus, they hypothesized this was due to buffering effects of cAMP binding 
proteins which reversibly bind, thus slowing diffusion. The idea that cAMP diffusion was largely 
9 
unimpeded by the intracellular environment became widely accepted. However, experimental 
evidence for PKA pools seemed to contradict these data. 
Mathematical modeling by Rich et. al. suggested if cAMP diffuses through a cell as it 
does in aqueous solutions, it would not accumulate to effective concentrations for activating 
effector proteins (109). Transmembrane ACs have a relatively slow rate of catalysis, generating 
about 59 molecules of cAMP every second (110). The concentration of cAMP, even 5 nm from 
AC, would be ~10-fold lower than the concentration needed to achieve half maximal activation 
(K1/2) of PKA, ~100-fold lower than the K1/2 of EPAC, and ~10,000-fold lower the K1/2 of 
olfactory nucleotide-gated channels (111,112). While comparing protein activation constants 
does not necessarily recapitulate in vivo signaling, there are other problems with the concept of 
unhindered cAMP diffusion. For example, it could lead to activation of distant effector proteins 
throughout the cell, contradicting GPCR activation of different PKA pools. Mathematical models 
indicate co-localization of AC and PDEs are not sufficient for generating physiologically 
relevant cAMP gradients (113,114). Hence, models relying on proximity alone is not enough for 
cAMP activation of specific signalosomes.  
Rich et. al. compared cAMP concentrations using membrane cyclic nucleotide-gated 
channels and cytosolic PKA-based FRET (Fluorescence Resonance Energy Transfer) sensors 
(109). They found under the same stimulating conditions in C6-2B glioma cells that membrane 
concentrations of cAMP were much higher (>12-fold) than cytosolic levels. Combining this 
knowledge with their mathematical models formed the two-compartment model of cAMP 
diffusion (111). The compartments refer to a smaller sub-cellular compartment such as near a 
site of cAMP production and the larger compartment of the bulk cytosol. The basic premise 
states cAMP diffusion between the two compartments is restricted or slower than the previously 
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assumed rate of diffusion. Upon stimulus of cAMP production, the activated cyclase produces 
cAMP in the smaller first compartment, leading to an initial spike in cAMP accumulation. Then, 
delayed activation of PDEs and diffusion with the second larger compartment lead to decreased 
cAMP accumulation in the first compartment. There is a subsequent increase in cAMP 
accumulation in the cytosol however it does not reach the same maximum as the smaller 
compartment. Other computational models confirm that a lower cAMP diffusion coefficient (10-
100-fold lower) created scenarios where membrane-localized effectors could be activated and 
physiologically relevant cAMP gradients could form (113,115). Although, some models found 
they could achieve compartment specific activation using unrestricted cAMP diffusion in their 
model using high, non-physiological levels of PDE activity and specific cell geometries (116), or 
using broadly distributed PKA-sensitive cAMP degradation, high cyclase activity, and high PDE 
activity (117,118).  A two-compartment system with restricted diffusion between the membrane 
and cytosol could absolve proximity-based models for cAMP activation of specific effector 
pools. 
1.2.2 Direct Measurements of cAMP Diffusion 
Intracellular diffusion of a molecule or protein depends mainly on three factors: cytoplasmic 
viscosity, molecular crowding causing collisions, and binding to mobile or anchored molecules 
(119). Most small molecules exhibit 3 to 8-fold slower diffusion rates in the cytosol compared to 
aqueous solutions (119,120). The previously measured rates of cAMP diffusion were at odds 
with budding experimental evidence of GPCR-mediated activation of distinct PKA pools. 
Mathematical models predicted cAMP diffusion needed to be at least 10-fold slower (~30 μm2/s) 
for effective accumulation, activation of effectors, and effective degradation by PDEs (113). The 
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previously described studies measuring cAMP diffusion relied on indirect methods for 
measuring cAMP. Recent, advances in live cell imaging have provided more direct 
measurements of cAMP diffusion and methods to monitor cAMP accumulation with high spatio-
temporal resolution.  
To more directly measure cAMP diffusion in live cells, Agarwal et. al. used Raster 
Imaging Correlation Spectroscopy to measure diffusion of a fluorescent cAMP analog, 8-
[Pharos-450]-cAMP (ϕ450-cAMP), in HEK293 cells and adult cardiac myocytes (121). They 
obtained similar measurements of 5-10 μm2/s in both cell types, suggesting cell morphology was 
not a major factor. Rather, they noted ϕ450-cAMP co-localized with PKA-RII regulatory units in 
cardiac myocytes, indicating a majority of the cAMP analog was binding to anchored PKA, 
particularly at the mitochondria. Consistent with this finding, the rate of PKA-RII diffusion was 
similar to the diffusion of ϕ450-cAMP. Disrupting AKAP-PKA binding increased the rate of 
PKA-RII and ϕ450-cAMP diffusion to ~33 μm2/s, demonstrating PKA buffering accounts for a 
3-fold reduction in cAMP diffusion in adult cardiac myocytes. It is important to note ϕ450-
cAMP is resistant to PDE4 hydrolysis which represents a major source of cAMP regulation. 
Another approach to measure cAMP uses FRET biosensors which are dynamic, cAMP-
sensitive, fluorescent probes that can be used to extrapolate relative concentrations. Richards et. 
al. expressed an EPAC-based FRET sensor in adult cardiac myocytes and stimulated cAMP 
production using a microperfusion apparatus to expose half the cell to β-adrenergic agonists 
(122). They found cAMP diffused at a rate of 32 μm2/s that was independent of cAMP 
concentration, intracellular acidity, PDE activity, and PKA buffering. Their measurements were 
similar to diffusion rates of other small compounds; hence they hypothesized a common physical 
mechanism restricts cAMP diffusion. They found neonatal cardiac myocytes which express far 
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fewer mitochondria and exhibit lower cellular tortuosity have slightly faster rates of cAMP 
diffusion (~3-fold). The mechanisms governing cAMP diffusion remained undetermined, 
however there is consistent evidence that intracellular cAMP diffusion is much slower than in 
aqueous solutions. This distinction helps bridge the gap between computational predictions and 
growing experimental evidence for cAMP compartmentalization. 
1.2.3 cAMP Compartmentalization Model 
cAMP compartmentalization provides a new conceptual framework to investigate signaling 
specificity. By a functional definition, cAMP compartments are local areas of high concentration 
that co-localize with cAMP effectors and disruption of these compartments impact specific 
downstream responses. Some have described cAMP ‘microdomains’ which are compartments 
that measure micrometers in diameter. The mechanisms governing the formation and 
maintenance of cAMP compartments are still unclear. Most agree some combination of co-
localization of cyclases and effectors, localized degradation, cAMP buffering, cAMP export, and 
physical barriers contribute (123). Compartmentalization of other second messengers including 
cyclic GMP, nitric oxide, and Ca+2 are also hypothesized to follow these proposed models (124). 
Localized cAMP production depends on differential AC isoform localization and activity. 
Transmembrane isoforms can co-localize with GPCRs through interactions with scaffolding 
proteins or with lipid rafts of the membrane. Additionally, sAC can localize in various 
subcellular regions through binding AKAPs. The cAMP compartmentalization model predicts 
cAMP accumulation near the source of synthesis can reach effective concentrations for 
activating effector proteins. Furthermore, these effectors are positioned via AKAP or other 
associated proteins in a manner which favors activation (Fig. 2A). To achieve high cAMP 
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concentrations, diffusion can be limited by physical and enzymatic boundaries. Physical barriers 
can include cellular viscosity and tortuosity, cell shape, and potentially barriers from organelles 
(Fig. 2B). For example, the endoplasmic reticulum can come in close contact with the membrane 
and potentially impede cAMP diffusion (109). Another model suggests the cortical actin 
cytoskeleton can serve as a diffusional barrier. Destabilizing actin cytoskeletal organization 
using latrunculin promoted cAMP diffusion from the membrane to cytosol in a cystic fibrosis 
cell line; this could be rescued by overexpressing the scaffolding protein Na(+)/H(+) exchanger 
regulatory factor (NHERF1) to re-establish cytoskeletal organization (125). Sub-cellular regions 
and compartments can also be protected from cAMP through localized PDE degradation. 
Multiple studies have shown PDE inhibition increases spreading of cAMP throughout the cell, 
concluding PDEs act as a barrier to limit diffusion in certain regions (87) (Fig. 2C). Others have 
found microdomains of low cAMP concentration where PDE functions as a sink (126,127) (Fig. 
2D).  Another mechanism slowing cAMP diffusion is buffering by cAMP effector proteins 
which limit the number of free, unbound molecules available (Fig. 2E). Lastly, cAMP can be 
exported through the cell via multidrug resistant proteins, although the rate of export is relatively 
slow (2x10-3/s) (118,128,129) (Fig. 2F). These fundamental concepts underly the growing 




Figure 2. Mechanistic models of cAMP compartmentalization. 
(A) Co-localization of ACs and cAMP effectors via AKAPs can favor activation of specific pathways. (B) Physical
compartmentalization by cell geometry, viscosity, tortuosity, or organelle barriers can promote cAMP accumulation. 
(C) PDEs can form barriers which prevent cAMP accumulation outside of compartments. (D) PDEs create
compartments with low cAMP, thus protecting effectors from activation. (E) Buffering by cAMP effectors can 
impede diffusion by limiting free cAMP. (F) MRPs can export cAMP from the cell. 
1.3 EVIDENCE FOR cAMP COMPARTMENTALIZATION 
Some of the first experimental and visual data supporting compartmentalization of cAMP used 
FRET-based approaches. Bacskai et. al. were the first to use cAMP FRET sensors to study 
diffusion in Aplysia sensory neurons using a PKA-based sensor called fluorescein-labeled 
catalytic subunit and rhodamine-labeled regulatory subunit (FlCRhR, pronounced “flicker”) 
(130). They found serotonin stimulated greater PKA activation in distal processes and minimal 
activation near the nucleus. They hypothesized this phenomenon could result from several 
factors: 1) serotonin receptors and/or cyclases were more concentrated at distal processes, 2) 
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cAMP diffusion was restricted, 3) PDEs exhibit differential effectiveness throughout the cell, 4) 
the sensor was perturbed in one part of the cell, or 5) the observed cAMP gradient resulted from 
the higher surface-to-volume ratio in distal processes. Interestingly, they found injected cAMP 
was freely diffusible (780 μm2/s), suggesting there were no obvious barriers for cAMP. They 
further concluded endogenous PDE activity and the sensor alone could not form cAMP 
gradients; rather, cell geometry was the primary factor establishing the gradient. The substantial 
discrepancy between physiological stimulus of cAMP gradients and artificial addition of freely 
diffusing cAMP emphasizes the impact of spatial regulation. While this initial study had a few 
drawbacks, including potential cAMP buffering by the sensor which could artificially favor 
gradient formation and microinjection of the sensor could introduce a cAMP sink from the 
needle (131), it was the first direct evidence of restricted cAMP diffusion. 
Zaccolo and colleagues were the first group which combined experimental evidence for 
cAMP compartmentalization and AKAP-mediated signalosomes (132). They created a PKA-
based FRET sensor which relied on dissociation of the regulatory and catalytic domains upon 
binding to cAMP (89,132). In cardiac myocytes they discovered β-adrenergic receptor 
stimulation with norepinephrine increased cAMP levels near T tubules/junctional sarcomere 
membrane compared to the cytosol. These compartments of high cAMP concentration could be 
as little as 1 μm in diameter, hence earning the title of ‘microdomains’. Inhibiting PDEs made 
this signature more evenly diffuse throughout the cell, suggesting PDEs were the main factor 
limiting cAMP diffusion and maintaining compartmentalization. They additionally hypothesized 
in their cell model that cyclases constitutively produced cAMP and that low PDE activity 
maintained basal cAMP levels. A few limitations of the assay are worth considering when 
interpreting the results. The sensor has slow kinetics since dissociation of the PKA heterotrimer 
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requires cooperative binding of four cAMP molecules (133). Additionally, intermolecular FRET 
interactions can occur between clustered sensors, and the sensor retains endogenous PKA 
activity and localization (133). To prevent sensor co-localization with AKAPs along the 
sarcomere, they made a truncated version which lacked the AKAP binding motif; however, they 
did not see the same high concentration cAMP pools. This suggests sarcomeric AKAPs represent 
a unique compartment for specific PKA activation.  
They further refined this study using PKA regulatory RI and RII subunits which bind to 
different AKAPs in cardiac myocytes (134). PKA-RII is primarily found in particulate fractions 
of M sarcomeric lines, while PKA-RI localized to Z and M sarcomeric lines. Both anchored to 
AKAP proteins and demonstrated comparable cAMP binding characteristics. Using the PKA-RI 
and RII AKAP anchoring motifs, they created RI and RII-targeted FRET sensors for cAMP 
using an EPAC-based sensor. They found isoproterenol stimulation of β-adrenergic GPCRs 
primarily activated RII-localized sensors, whereas prostaglandin E1 receptor stimulation 
primarily activated RI sensors. The cAMP signature for both the RI and RII compartments could 
be altered by perturbing AKAP binding of the individual sensor or inhibiting a specific, 
associated PDE isoform. These results demonstrate specific GPCRs can stimulate distinct cAMP 
pools which in turn selectively activate AKAP-associated PKA isoforms. Additionally, after 25 
years, it provided a potential mechanism behind the ‘PKA pool’ observations made by Buxton 
and Brunton (14). 
1.3.1 Compartmentalization of Membrane, Cytosol, and Nucleus 
After the initial experiments describing cAMP compartments and microdomains, several other 
studies have confirmed differential cAMP dynamics between the plasma membrane, cytosol, and 
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nucleus (115,135-137). These sub-cellular compartments are larger than the aforementioned 
microdomains, yet they still represent distinct regions where differences in cAMP accumulation 
have functional effects. Using cAMP FRET sensors localized to the plasma membrane and 
cytosol, researchers found cAMP accumulates and reaches higher concentrations in sub-
membrane regions. For example, prostaglandin E1 signaling stimulate higher amplitudes of sub-
membrane cAMP in HEK293 expressing lipidated PKA- and EPAC-based cAMP FRET sensors 
(137). PKA regulates the gradient formed between the membrane and cytosol through a negative 
feedback loop. Pharmacological, siRNA knockdown, and dominant negative approaches reveal 
PKA-dependent activation of PDE4D and PDE4B regulated cAMP levels in the membrane and 
cytosol, respectively. They hypothesized cAMP forms multiple contiguous compartments with 
different concentrations which depend on PDE activity. Interestingly, they found cAMP 
accumulation in the nucleus was higher than cytoplasmic levels and comparable to membrane 
accumulation. This contrasted earlier work from another group which also studied HEK293 cells. 
DiPilato et. al. found isoproterenol and prostaglandin E1 stimulates higher cAMP levels in sub-
membrane regions, compared to the cytosol and mitochondria-localized sensors; however, cAMP 
levels in the nucleus were lower than all other compartments measured (136). There was no 
substantial kinetic delay for cAMP entering the nucleus, but there was a significant delay in 
nuclear PKA activation compared to cytosolic PKA. The delayed timeframe was consistent with 
slower translocation of the catalytic subunit from membrane-activated PKA pools rather than 
direct activation of a nuclear PKA pool (138,139). The presence of cAMP in the nucleus, which 
demonstrates differential regulation from other sub-cellular compartments, presents an 
interesting case. 
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Sample et. al. was the first group to prove a functional pool of nuclear PKA existed. They 
combined targeted FRET sensors to measure cAMP concentrations and PKA activity with a 
truncated, catalytically active sAC localized to the membrane, cytosol, and nucleus (135). This 
technique allowed activation of cAMP production with bicarbonate in different compartments 
while measuring cAMP and PKA activity in real time. They found cAMP production at the 
membrane exhibited low nuclear cAMP levels and delayed nuclear PKA activity. The ~20 min 
delay in PKA activation despite the presence of cAMP in the nucleus was consistent with the 
cPKA translocation. cAMP production from the cytosol and nucleus exhibited lower membrane 
cAMP levels, rapid PKA activity in the nucleus (~3-4 min), and faster phosphorylation of 
CREB. This suggested a pool of PKA was present in the nucleus which is not activated by 
membrane-localized cAMP production in this model. They further verified the full PKA 
holoenzyme was present in the nucleus and hypothesized a PDE/AKAP/PKA complex regulated 
activation in the nuclear compartment. 
1.3.2 Small Scale Compartmentalization 
Small scale compartments and microdomains have also been identified in membrane lipid rafts, 
endosomes, presynaptic boutons, AKAP-localized regions, and mitochondria (127,140-144). 
Collectively these show regions of high or low cAMP concentrations exist and can co-localize 
with clusters of effector proteins. Again, this is achieved by close physical proximity to cyclases 
(AKAP/lipid rafts), physical sterics (cell shape), and enzymatic barriers (localized PDE). This 
section will focus on experimental proximity-based models as it is more relevant to this thesis. 
Researchers have proposed lipid-raft and non-raft organization of the plasma membrane could 
help establish cAMP compartments; however, more comprehensive experimental evidence is 
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required. Depry et. al. used localized PKA-substrate (AKAR) FRET sensors targeting raft 
(myristolyated/palmitoylated) and non-raft (farnesylated) membrane regions in HEK293 (145). 
They found higher basal cAMP activity in raft regions, however their findings could not control 
for differences in PKA expression in the regions. A complementary study using similarly 
targeted cAMP FRET sensors in HEK293 found somewhat contrary results concluding basal 
cAMP levels are higher in non-raft regions. This study further compared raft and non-raft cAMP 
levels with raft-associated β2-adrenergic receptor and non-raft associated prostaglandin receptor 
stimulation (140,146). They found no striking difference between compartments, however 
interfering with rafts via cholesterol depletion selectively reduced β2-adrenergic stimulated 
cAMP levels. Similar studies were conducted in airway smooth muscle cells using targeted 
cAMP FRET sensors (147). Stimulation of β2-adrenergic signaling exhibited increased cAMP 
levels throughout the cell, while butaprost stimulation of prostaglandin receptors increased 
cAMP levels specifically in non-raft and nuclear localized compartments. Butaprost stimulation 
in the presence of a PDE4 inhibitor resulted in increased cAMP levels in all measured 
compartments, including the raft and cytoplasmic regions. Taken together with other studies on 
this subject, lipid rafts and non-raft membrane organization may provide an environment for 
effective clustering of GPCRs, associated ACs, and cAMP regulatory machinery for favoring 
cAMP compartment formation. However, advances in spatial resolution and additional methods 
for altering raft domains may be needed to substantiate this model.  
Combination approaches lead to the most convincing evidence for lipid-raft-mediated 
cAMP compartmentalization. Averaimo et. al. combined localized FRET measurements, cAMP 
signaling interference, and stimulation in retinal ganglion cells (148). They hypothesized AC1 
localization to membrane lipid rafts represented a potential cAMP compartment which regulates 
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ephrin-A-stimulated axonal retraction. Using EPAC-based FRET sensors localized to raft and 
non-raft membrane domains, they found ephrin-A5 stimulated a reduction in cAMP levels 
specifically in raft compartments. They found mimicking this effect, using a localized cAMP 
sponge to reduce cAMP levels, produced a similar response. Raft-associated cAMP reduction 
promoted axon retraction whereas non-raft cAMP reduction did not. Notably, expressing a 
cAMP binding-deficient mutant of the cAMP sponge did not elicit the same effects, showing 
their approach did not interfere with compartmentalization. Lastly, they found localized bPAC, 
when activated transiently, could induce PDE activity and ultimately reduce local cAMP. 
Reducing cAMP with this method in raft-compartments specifically stimulated axon retraction. 
While the use of bPAC to reduce cAMP levels is rather unconventional, particularly since their 
FRET recordings also excited bPAC inadvertently, they were able to distinguish cAMP 
dynamics in two compartments with close proximity. They further tested this effect in vivo to 
show that the raft-localized cAMP sponge interfered with axon arbor refinement whereas a non-
raft localized cAMP sponge and a raft-localized mutant sponge had no effect on axon arbor 
development. 
Others have approached identifying cAMP compartments by probing AC and AKAP-
mediated signalosomes. Wachten et. al. investigated AC8-associated cAMP pools by fusing a 
cAMP FRET sensor to a catalytically inactive AC8 (142). They compared this to membrane 
(myristoylated/palmitoylated) and cytosolic localized sensors in GH3B6 pituitary cells. Gαs-
stimulated cAMP production increased cAMP levels at the membrane and cytosol, but not in 
AC8-localized membrane compartments. Gαq-stimulated Ca+2 signaling, which typically inhibits 
AC5/6, decreased cAMP levels at the membrane and cytosol, but increased cAMP proximal to 
AC8. Although the AC8 and lipid-modified FRET sensors both reside at the membrane, they 
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exhibited distinct cAMP dynamics. This provides evidence that AC isoform specific cAMP 
compartments can exist. AKAP-mediated compartments became a field of study after 
discovering peptide-based disruption of its interaction with PKA severely hindered PKA 
activation (67,149). AKAPs are hypothesized to increase local effective concentrations for 
protein interactions and accelerate activation anywhere from 4 to 20-fold faster than in solution 
(71). Scott and colleagues identified a signalosome consisting of muscle-specific AKAP 
(mAKAP), PKA, EPAC1, and PKA-activated PDE4D3 (68). They show PDE4D3 tethering to 
PKA reduces PKA activation, suggesting this AKAP-mediated signalosome incorporates a 
negative feedback loop to terminate cAMP signaling. Another example of this is AKAP79 which 
has been shown to bind β-adrenergic receptors, AC5, and PKA (72,74). PKA phosphorylation of 
cyclase 5 represses cAMP synthesis, thus creating an environment where GPCR-stimulated 
cAMP synthesis is quickly downregulated (74). Proximity based models of co-localized sites of 
cAMP synthesis and cAMP effectors is foundational to the compartmentalization paradigm. 
The field of cAMP compartmentalization has made substantial progress in the last two 
decades largely due to advances in imaging technology. The compartmentalization paradigm is 
well-recognized; however, it is not fully accepted. Limitations in the methods applied have left a 
few gaps. For example, the term ‘compartmentalization’ implies these are rigid and static when 
they are in fact highly dynamic. The borders and size of compartments are not well defined and 
based on interpretation. Some studies prefer the term ‘location-biased cAMP signaling’ rather 
than compartmentalization since cAMP is still found throughout the cell and not tightly 
constrained. Regardless, they all agree uneven distribution of cAMP throughout the cell has 
potential physiological consequences. Furthermore, concepts from the cAMP 
compartmentalization paradigm are being applied to disease models (150-152). Since many 
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cAMP compartments have not yet been explored, there is a clinical need for identifying new 
compartments. Here, we have characterized a potential Radixin-associated cAMP compartment 
in thyroid epithelial cells and created novel tools to advance the field. 
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2.0  TSH/cAMP SIGNALING PROMOTES THYROID CELL PROLIFERATION 
2.1 INTRODUCTION 
2.1.1 TSH is a Master Regulator of Thyroid Function 
The thyroid is a major endocrine gland that regulates cellular metabolism throughout the body. 
This butterfly shaped organ consists of two lobes, located on either side of the trachea connected 
by a thin section of tissue known as the isthmus. Each lobe contains follicles lined with epithelial 
cells that are responsible for producing and secreting thyroid metabolic hormones 
triiodothyronine (T3) and thyroxine (T4) in response to thyroid stimulating hormone (TSH) 
(153). TSH is a glycoprotein secreted from the pituitary gland that serves as the master regulator 
for thyroid function. The ligand binds to its receptor (TSHR) at the basal side of thyroid 
follicular cells to stimulate multiple cell processes including cell differentiation, attachment, 
iodine intake, thyroid metabolic hormone production/secretion, and most relevant to this thesis, 
proliferation (154). Hence circulating TSH levels are carefully regulated by the body through a 
negative feedback mechanism known as the hypothalamic-pituitary-thyroid axis. Under normal 
circumstances, the hypothalamus produces the thyrotropin-releasing hormone which stimulates 
TSH production in the pituitary gland. TSH signaling at the thyroid elevates circulating levels of 
the thyroid hormones. T3 and T4 then negatively affect hypothalamus production of thyrotropin-
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releasing hormone, thus reducing TSH production. This negative feedback axis in addition to 
other regulatory mechanisms of TSH production result in short pulses of circulating TSH. TSH 
pulses occur slightly less than every two hours and reach higher amplitudes at night, following a 
circadian rhythm (155).  
As with most highly regulated pathways, irregularities in TSH signaling can lead to 
thyroid disorders such as hyper/hypothyroidism, goiters, hyperplasia, and adenoma. With 
improved diagnostic methods for detecting thyroid cancer, the population of affected patients has 
risen over the last decade (156); hence, the role of the TSH pathway in cell proliferation sparks 
immediate attention. The next section discusses the major players in TSH-mediated proliferation. 
2.1.2 TSH Stimulates cAMP-Dependent Proliferation 
The interaction between the TSH ligand and TSHR follows canonical models of GPCR signaling 
(Fig. 1). TSHR is a classic A family GPCR where TSH promotes the activation of Gαs and 
Gαq/11 (157). Both pathways have been shown to promote proliferation; however, Gαs shows a 
higher affinity for TSHR binding and has a well-characterized role in cAMP-dependent 
proliferation. cAMP signaling transduces most of the effects of TSH on thyroid cells (158). 
Mutations in this pathway that render constitutive cAMP signaling have been linked to thyroid 
hyperproliferative disorders. Ledent and colleagues were the first to show constitutive cAMP 
signaling caused hyperthyroidism and goiter formation in transgenic mice expressing the 
adenosine A2a receptor (159). This proof of concept was supported by similar studies with 
constitutive Gαs activity which instigated hyperfunctioning thyroid adenoma and hyperplasia 
(160,161). Furthermore, characterization of human thyroid adenomas revealed somatic mutations 
in the TSHR which exhibit constitutive cAMP signaling (162,163). Patients with McCune-
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Albright syndrome, which have an activating Gαs mutation, also exhibit goiters and thyroid 
nodules (97,164,165). Hence, understanding the mechanism regulating cAMP signaling in 
thyroid proliferation is clinically imperative. 
TSH/cAMP stimulated proliferation in thyroid cells additionally requires the presence of 
a co-mitogen such as insulin, IGF-1, or serum. Roger et al (166) showed TSH alone could not 
promote proliferation in primary canine thyroid epithelial cells in the absence of insulin or 
serum. It was later discovered in primary canine thyroid cells that insulin/IGF-1 and TSH/cAMP 
signaling separately control cell growth and DNA synthesis, respectively (167). Insulin or IGF-1 
was required to increase cell mass and had a permissive effect on TSH-stimulated DNA 
synthesis. This co-mitogen requirement has been shown in several thyroid models (168). The 
resulting model suggests insulin/IGF-1 stimulates upregulation of cyclin D3 and cAMP-
dependent activity is required for forming cyclin D3 complexes with cyclin dependent kinase 4 
(CDK4) (169,170). Since TSH specifically promotes the G1 to S phase transition, the next 
sections will focus on mitogenesis rather than the full spectrum of events throughout cell 
proliferation. 
cAMP exerts its effects on mitogenesis primarily through activation of PKA and EPAC. 
Studies in several thyroid models show PKA is required for effective stimulation of DNA 
synthesis, however it does not account for the full effect (171-173). The small Ras-like GTPase, 
Rap1, was identified as another key factor in TSH-mediated mitogenesis. This helped identify 
EPAC as a cAMP-dependent GEF which activated Rap upon TSH stimulation. While some 
reports found the role of EPAC in cell mitogenesis was independent of PKA (174,175), our lab 
found its effects required PKA activity in PCCL3, an epithelial thyroid cell line derived from rats 
(176,177). PCCL3 are a unique model for thyroid studies since they retain several characteristics 
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of thyroid cells including TSH-dependent growth, iodine uptake, and expression of 
differentiation markers like thyroglobulin and thyroperoxidase (168). PCCL3 are considered pre-
cancerous since they require two retroviral oncogenes for transformation, while other thyroid cell 
lines like FRTL-5 only require one (168,177).  
2.1.3 Radixin-PKA-EPAC Complex Role in Mitogenesis 
Using the PCCL3 cell line, our lab established a mechanistic model for the role of EPAC in 
TSH-mediated mitogenesis (176). We found that TSH stimulated EPAC activation of Rap1b. 
Specific activation of EPAC using the cAMP analog 8-pMeOPT-2′-O-Me-cAMP (178) did not 
stimulate mitogenesis by itself, however it significantly increased the proliferative effect of the 
PKA-specific activator 6-Bz-cAMP (179). This suggests EPAC and PKA work in a synergistic 
manner (176). Using a dominant negative approach, our lab found that expressing a truncated 
form of EPAC that lacked the catalytic domain but retained the N-terminal DEP domain for 
localization blocked endogenous EPAC activity and prevented TSH-stimulated mitogenesis. This 
revealed that EPAC was necessary for transducing TSH/cAMP-dependent mitogenesis and that 
the location of EPAC was critical for its role. 
Searching for potential DEP domain binding partners of EPAC, we identified Radixin in 
a yeast two-hybrid assay using the N-terminus of EPAC as bait (79). Radixin is an ERM family 
protein that binds the actin cytoskeleton at its C-terminus and membrane-associated proteins at 
its N-terminus in its active form (180). In its inactive form, the N and C-termini associate, 
creating an auto-inhibited closed conformation which prevents actin and membrane interactions 
(181,182). In vitro pulldown assays confirmed the interaction between the N-terminus EBD 
domain of EPAC and the N-terminal FERM (Four.1, Ezrin, Radixin, Moesin) domain of 
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Radixin. EPAC and Radixin co-localize in sub-membrane regions in clusters (79). We further 
examined whether Radixin served as a scaffolding protein for PKA.  
Since the N and C-termini of Radixin can interact, truncated forms of either terminal 
domain can interfere with ERM function (183,184). Hence expression of a truncated Radixin C-
terminal fragment disrupted EPAC localization to sub-membrane clusters. Interestingly, a N-
terminal fragment of Radixin did not interfere with EPAC localization or TSH signaling. The 
Radixin C-terminus disrupted TSH-mediated mitogenesis; however, this could be rescued by 
expressing a Rap1b mutant. Rap1b expression rescued mitogenesis only when it was 
constitutively active and had a phospho-mimetic mutation, therefore bypassing the need for 
EPAC activation and PKA phosphorylation of Rap1b (79). Since disruption of the Radixin 
complex was rescued by the double mutant Rap1b, the data suggest the only role of the Radixin-
PKA-EPAC complex is to position PKA and EPAC in an area of high cAMP for effective 
transduction of TSH signaling. Hence, we hypothesize a Radixin-associated cAMP compartment 
plays a role in TSH-mediated thyroid cell mitogenesis. Here, we show evidence for increased 
cAMP accumulation in Radixin-associated sub-membrane compartments using the N-terminus 




Figure 3. TSH/cAMP-stimulated mitogenic pathway. 
TSH binding to its receptor activates Gαs which in turn activates transmembrane ACs. AC converts ATP into cAMP 
where it activates the GEF EPAC and the kinase PKA which are both anchored by the cytoskeletal scaffolding 
protein Radixin. EPAC and PKA synergistically promote mitogenesis through their actions on Rap1b. The EPAC-
Radixin-PKA complex is hypothesized to co-localize with a region of high cAMP concentration. 
2.2 METHODS 
2.2.1 Cell Culture and Transfection 
The rat thyroid follicular cell line, PCCL3, was grown in F12 Coon’s modified media 
supplemented with 2.68 g/L sodium bicarbonate, 5% fetal bovine serum (FBS), 
Penicillin/Streptomycin, L-glutamine, and 4 Hormone solution: insulin (1 μg/mL), apo-transferin 
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(5 μg/mL), hydrocortisone (1 nM), and thyroid stimulating hormone (1 IU/L) (Complete Coon’s 
media). Cells were grown to ~90% confluency before passaging every 2-4 days at 37°C in 5% 
CO2, 95% humidified air. For transient transfections, cells were transfected 24 hs after plating 
using Xtremegene HP (Roche) or Lipofectamine 3000 (Thermo Fisher Scientific) for PCCL3 
cells. Cells were cultured for 24 hr and given fresh media.  
2.2.2 Plasmid Construction 
A codon optimized N-Radixin (N-Rx, amino acids 1-318) sequence for mammalian expression 
with flanking HindIII sites was synthesized by Geneart. The sequence was subcloned using these 
cut sites upstream of the Epac1-cAMPs FRET sensor (88). The N-Rx sequence was also 
subcloned into pcDNA3.1+-bPAC-myc-mCherry (Addgene) using HindIII restriction enzymes. 
Plasmids pSiren-dsRed and pCMV-myc-empty vector were purchased from Clontech. 
2.2.3 Immunocytochemistry 
PCCL3 cells were seeded in a 6-well dish on gelatin-coated glass coverslips (25 mm, #1.5, 
Warner Instruments), transfected, washed with PBS, fixed 10 min in 4% PFA, and permeabilized 
10 min with 0.5% Triton X-100. Cells were stained with DAPI, mounted, and imaged on an 
Olympus Confocal Fluoview FV1000, 60x/NA 1.45. 
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2.2.4 Real-Time FRET Imaging 
1.5x106 cells were seeded on 0.1% gelatin-coated glass coverslips for 24 hr, transfected, and 
given fresh media the next day. Cells were hormone starved for 3 hr prior to imaging in Coon’s 
media with 5% FBS and lacking TSH, Insulin, and hydrocortisone (Starvation Coon’s media). 
Cells were washed twice with PBS and imaged in OptiMEM lacking phenol red on an Olympus 
IX70 microscope equipped with a Till Poly V monochromator. Images were acquired every 10s 
with a 60x/1.4 NA oil objective, 8x8 binning and a Hammamatsu CCD camera using 440nm 
excitation with emission filters 470/30 and 535/30 and dichroic 455 DCXR. Data was collected 
using Slidebook software containing the appropriate two-channel (intramolecular FRET) or three 
channel (intermolecular FRET) correction modules (channel bleed-through and direct acceptor 
excitation). The PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) is added at the end of each 
experiment to find the maximal saturation point of the sensor. 
2.2.5 BrdU Incorporation Assay 
1.5x106 cells were seeded on 0.1% gelatin-coated glass coverslips for 24 hr, transfected, and 
given fresh media the next day. 24 hr after transfection, cells were hormone starved in Starvation 
Coon’s media with 5% FBS for 16 hr. Media was replaced with fresh starvation Coon’s media 
containing 5% FBS and either kept in darkness or stimulated with 4.41 ± 0.30 μW/mm2 450 nm 
light for 500 ms every 15 min over 24 hr (royal blue CREE XTE, LED Supply). The LED 
control system is described in greater detail in the next chapter. 8 hr after stimulation, 100 μM 
BrdU was added using a small volume and incorporated over 16 hr. Then cells were washed in 
PBS, fixed for 10 min in 4% PFA, and permeabilized 10 min in 0.5% TritonX-100. Cells were 
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washed and incubated with primary antibody anti-BrdU (Caprilogics) in 3% bovine serum 
albumin with RQ1 DNase I (1:100, Promega), 5mM MgCl2, and 1mM CaCl2. Secondary 
antibody anti-sheep Alexa 488 (1:1000 Jackson Labs) and DAPI were used. Images were 
acquired using a 20x/0.70 NA HC PLAN APO objective on a Leica DM500B microscope. 
Images were analyzed in Image J counting % BrdU positive nuclei/total DAPI stained nuclei. 
2.3 RESULTS 
2.3.1 Radixin-Associated cAMP Compartment 
As previously described, the N-terminus of Radixin (N-Rx, amino acids 1-318) did not interfere 
with EPAC localization or TSH-mediated mitogenesis (79). Thus, it presents a unique 
opportunity to investigate Radixin-localized sub-membrane compartments. Using an EPAC-
based FRET sensor, Epac1-cAMPs (Ep1) (88), we can measure real-time cAMP dynamics in 
PCCL3 cells. We modified the Ep1 sensor to include the N-Rx motif (N-Rx-Ep1) to target this 
construct to EPAC-Radixin-PKA compartments (Fig. 4A). The N-Rx-Ep1 sensor co-localizes 
with Radixin, indicating the membrane targeting mechanism is not limiting (Fig. 4B). We found 
that adding the N-Rx motif to a similar FRET sensor did not alter cAMP binding affinity (Fig. 
24). Consistent with our hypothesis and the two-compartment model, N-Rx-Ep1 senses ~2-fold 
higher cAMP levels compared to the cytosolic Ep1 sensor (Fig. 4C-D). This higher amplitude is 
transient and decreases to levels matching the cytosolic sensor. PDE activity is responsible for 
this decline, particularly PDE4 (data not shown). The differential cAMP dynamics found in 
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Radixin-localized domains is consistent with the compartmentalization model, hence for 
conventional purposes we refer to this as the Radixin cAMP compartment. 
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Figure 4. Targeted FRET sensors demonstrate higher cAMP levels in the Radixin-localized compartments 
upon TSH stimulation. 
(A) The Ep1 construct consists of a YFP/CFP FRET pair and a cAMP binding domain (CBD). We incorporated an
N-Radixin segment to target the sensor to the EPAC-Radixin-PKA compartment. (B) The targeted FRET sensor, N-
Rx-Ep1, co-localizes with Radixin. (C-D) TSH (1 mU/mL) stimulation in PCCL3 cells produces higher cAMP 
levels near the targeted sensor, N-Rx-Ep1, compared to cytoplasmic sensor, Ep1. Inhibition of PDE activity, via 
IBMX (250 μM), promotes a sustained cAMP signal and confirms the TSH peak is not due to probe saturation. 
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2.3.2 N-Radixin Localized cAMP Production Stimulates Mitogenesis 
Our model of the EPAC-Radixin-PKA compartment suggests that a co-localized cAMP pool is 
necessary for TSH/cAMP-mediated mitogenesis. Hence, spatio-temporal regulation of cAMP 
dynamics near this complex may be necessary for maintaining pathway specificity. We 
hypothesized local stimulation of cAMP production near the EPAC-PKA effector compartment 
will promote mitogenesis. There are a limited number of cAMP modulating tools with spatial 
and temporal accuracy, however the growing field of optogenetics offers unique opportunities 
for refined regulation of protein activity (185). The photoactivated adenylyl cyclase from 
Beggiatoa (bPAC) produces cAMP upon 435-455 nm light exposure within milliseconds, 
providing distinct temporal control (186). We modified this cytoplasmic protein to include an N-
Rx sequence to target the protein to the EPAC-PKA effector compartment (Fig. 5A-B), thus 
adding spatial regulation. bPAC-mCherry exhibits localization throughout the cytosol and 
nucleus. N-Rx-bPAC-mCherry co-localized with Radixin-GFP, suggesting it was effectively 
localized to Radixin-associated sub-membrane domains. Basal activity of the cytosolic and N-Rx 
bPAC constructs increased BrdU incorporation under dark conditions. Despite the high basal 
level of activity, stimulation with light increased the population of cells entering the S phase in 




Figure 5. Cytosolic and N-Rx-localized bPAC stimulates mitogenesis. 
(A) The N-terminal of Radixin (1-318) was added to the photoactivated adenylyl cyclase from Beggiatoa (bPAC)
containing a myc tag and mCherry fluorescent marker. (B) This sequence sufficiently localizes the protein in the 
same submembrane compartment as Radixin and is thus positioned near EPAC-Radixin-PKA signalosomes. (C) 
PCCL3 cells starved of TSH were stimulated with 450 nm light from and LED in pulses of 500 ms every 15 min 
over 24 hr or kept in the dark (37°C, 5% CO2).  BrdU incorporation marks cells entering the S phase. While 
cytosolic bPAC had higher expression levels, both constructs could induce proliferation (Mean +/- S of n=3-4,  >500 
cells per sample,  Two-way ANOVA, * = P<0.05, **= P<0.005). 
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2.4 DISCUSSION 
Here, we have identified a sub-membrane cAMP compartment associated with Radixin. The 
ERM family of cytoskeletal scaffolding proteins has become increasingly relevant in 
understanding AKAP-mediated cAMP signalosomes (187,188). N-Rx represents a unique motif 
to explore Radixin-localized sub-membrane domains as it does not appear to interfere with 
Radixin or EPAC localization at the membrane (79). Furthermore, we demonstrate increased 
cAMP levels in this compartment compared to the bulk cytosol, consistent with the two-
compartment model of compartmentalization (111). More work is needed to verify the existence 
of the Radixin cAMP compartment although we already have some functional evidence that 
cAMP generated here is sufficient to trigger mitogenesis. The majority of N-Rx targeted FRET 
sensor appears in the sub-membrane region; however, there may be non-membrane populations 
and membrane populations which are not proximal to the EPAC-Radixin-PKA signalosome. 
Still, this method indicates Radixin-localized regions experience different cAMP dynamics 
compared to the bulk cytosol upon TSH-stimulation. It would be interesting to compare this to a 
more general membrane-localized FRET sensor to test whether Radixin cAMP dynamics are 
distinguishable from other membrane regions. Some studies have found distinct cAMP dynamics 
in different sub-membrane compartments (141,148); however, others have found it difficult to 
measure cAMP with localized FRET sensors alone. Our results support evidence for differential 
cAMP signaling between the membrane and bulk cytosol. While we are uncertain which 
mechanisms restrict cAMP or maintain this gradient, we have evidence that PKA-sensitive PDE4 
is the major player responsible. Inhibition of PKA with H89 or inhibition of PDE4 with rolipram 
converts the transient TSH-stimulated cAMP signal into a sustained signal (unpublished data). 
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Hence the transient signature is likely maintained by a negative feedback loop of cAMP 
activation of PKA, PKA activating phosphorylation of PDE4, and PDE4 degradation of cAMP. 
Radixin-localized and cytosolic cAMP production using bPAC promoted mitogenesis. 
Despite high basal activity, we were still able to see increased proliferative levels by stimulating 
with pulses of blue light over 24 hr. Consistent with our hypothesis, Radixin-localized cAMP 
was able to stimulate mitogenesis. Interestingly, cytosolic cAMP production also stimulated 
mitogenesis. There are a few potential possibilities to explain why both constructs stimulated this 
effect. Since cells were transiently transfected for these experiments, bPAC was overexpressed 
and may have saturated the regulatory machinery such that cAMP could access both 
compartments. Alternatively, these results could suggest both membrane and cytosolic 
compartments play a role in TSH/cAMP mitogenesis. The role of transmembrane ACs in thyroid 
cell proliferation is well documented; however, the role of sAC is not known. We have found 
sAC is expressed in PCCL3 cells in the sub-membrane regions, cytosol, and nucleus. 
Furthermore, inhibition of sAC with KH7 was able to block TSH-mediated proliferation, 
suggesting a role for a secondary pool of cAMP activity. While other possible explanations exist 
may explain our results, key experimental changes must be made. 
To reduced basal levels of activity, we have since worked to reduce extraneous light 
exposure and lower protein expression. Long-term solutions to this problem, such as changing 
the promotor region or creating an inducible system, are described in chapter 3. Furthermore, to 
effectively compare compartments, future work will include altering the duration and intensity of 
light to create a dose-response curve. Comparing the potency between groups will more 
accurately compare responses, rather than relying on one stimulating condition. Overall, the 
results for a sub-membrane Radixin-localized pool of cAMP, the necessity for EPAC-Radixin-
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PKA complex formation and activity, and pro-mitogenic effect of Radixin-localized cAMP 
production support our model for the Radixin-cAMP compartment. More work is required to 
dissect location-biased cAMP signaling in thyroid cells; however, there are few tools which can 
alter cAMP dynamics with sufficient spatial and temporal resolution. Hence, the next section 
describes our work to addresses this gap in the field by creating a bPAC-based toolset with 
greater temporal regulation. 
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3.0  LUMINESCENCE-ACTIVATED CYCLASE ALLOWS DUAL PHOTO AND 
CHEMICAL ACTIVATION OF cAMP SYNTHESIS 
3.1 INTRODUCTION 
3.1.1 Current Methods for Measuring and Modulating cAMP 
The cAMP compartmentalization model has become a prominent explanation for how cAMP 
activates specific pathways. Although the hypothesis of cAMP compartmentalization was 
proposed 40 years ago, we are finally gaining mechanistic data including more direct 
measurements of cAMP diffusion and the identification of specific compartments. This section 
reviews current methods for monitoring cAMP and interfering with localized signaling. 
Additionally, we outline the gap in available methods used for synthetically modulating local 
cAMP production and introduce a novel toolset for answering said problem. 
3.1.2 Fluorescence Resonance Energy Transfer Biosensors 
cAMP production and degradation occur on the seconds to minutes timescale. Historically, 
antibody-based detection in cell lysates was unable to achieve refined measurements with much 
temporal accuracy let alone spatial accuracy. CNGs could be used to monitor cAMP signaling 
with great temporal accuracy, however it was only possible to measure membrane cAMP 
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dynamics. FRET-based technology has emerged as the primary means of detecting cAMP in live 
cells with exquisite spatio-temporal specificity. FRET takes advantage of a phenomenon that 
occurs between two fluorophores in close proximity. If the emission spectrum of one fluorophore 
sufficiently overlaps the excitation spectrum of another, then the excited donor fluorophore can 
transfer energy to the acceptor fluorophore through non-radiative dipole-dipole coupling. This 
results in increased acceptor fluorophore emission and quenching of donor fluorescence. FRET 
occurs only when the two fluorophores have sufficient spectral overlap (Fig. 6B), are in close 
proximity (1-10 nm), have parallel transition dipole orientations, and when the donor has a 
sufficient fluorescence lifetime for FRET (189,190). FRET sensors designed to monitor cAMP 
usually contain a CBD derived from PKA or EPAC which, when bound to cAMP, undergoes a 
conformational shift that alters the distance between fluorophores. For example, in the previous 
section we used Epac1-cAMPs which uses an ECFP and EYFP FRET pair with a connected 
CBD domain from EPAC1 (Fig. 6A). When unbound, the two fluorophores are in close 
proximity and FRET occurs upon excitation of ECFP. Once bound to cAMP, the fluorophores 
are separated and there is a loss of FRET signal. Typically, measurements are expressed as a 
ratio of acceptor fluorescence over donor fluorescence with additional corrections for 
background fluorescence, direct activation of the acceptor fluorophore, and photobleaching. To 
more easily communicate the data, we express it as a ratio of donor over acceptor fluorescence 




Figure 6. Fluorescence resonance energy transfer biosensors. 
(A) The cAMP FRET sensor Epac1-cAMPs consists of an ECFP and EYFP FRET pair with a connecting CBD
derived from EPAC1. FRET occurs in the absence of cAMP; upon binding it undergoes a conformational shift that 
decreases FRET efficiency. (B) FRET occurs between fluorophores with sufficient spectral overlap, i.e. the emission 
of the donor fluorophore overlaps with the excitation spectrum of the acceptor fluorophore (Data adapted from 
ThermoFisher Scientific Fluorescence SpectraViewer). (C) The change in fluorescence is expressed as the 
normalized ratio of YFP FRET emission over CFP emission such that an increase in cAMP will appear as an 
increase in FRET ratio. 
The first visualization of cAMP compartmentalization used the FlCRhR sensor which 
was introduced by Tsien and colleagues (191). It consisted of fluorescein-labeled PKA catalytic 
subunits and rhodamine-labeled regulatory units where cAMP induced dissociation of the 
subunits which led to a loss of FRET. While this was unprecedented at the time, several caveats 
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prevented widespread adoption of the technique. It required isolation of the protein, 
microinjection into individual cells, and retained endogenous PKA activity (192). Zaccolo and 
colleagues improved this approach by introducing a genetically encoded sensor with a GFP-
labeled catalytic PKA subunit and blue GFP variant (EBFP) PKA regulatory RII subunit (89). 
The fluorophores were later changed to a CFP and YFP FRET pair which are more resistant to 
photobleaching (132). cAMP FRET sensors derived from PKA are commonly used (192), 
however many still retain endogenous PKA activity and localization. Buffering by PKA can also 
play a large role in interfering with measurements (193). This was used to Hofer and colleagues’ 
advantage where they designed a ‘cAMP sponge’ from the RIIβ subunit of PKA to reduce cAMP 
levels (194); however, it illustrates a major drawback of PKA-based FRET sensors. Additionally, 
the slow kinetics of PKA dissociation and reassociation limit the temporal resolution. 
Unimolecular probes are more advantageous because they guarantee a one to one ratio of 
acceptor and donor fluorophores, thereby reducing additional controls needed. Hence, one of the 
most recently developed PKA-based FRET sensors is a unimolecular probe, Riα #7. This sensor 
exhibits high cAMP affinity (~33 nM) and has been used to measure low extracellular levels of 
cAMP. It consists of a R1α subunit sandwiched between circularly permuted Venus and CFP 
fluorophores (195). Circular permutation of fluorophores is a method which reorients 
fluorophores for more efficient energy transfer; the N and C termini of the fluorophore are joined 
while new termini are made at permissive sites (195,196). 
After EPAC was discovered (75,76) several unimolecular cAMP FRET sensors were 
derived from this sequence. The EPAC class of sensors demonstrated higher FRET efficiency 
and more rapid kinetics compared to PKA sensors (88,192). The first EPAC-based FRET sensors 
were published in 2004 from three different research groups, each with a unique variant 
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(88,136,197). Researchers found removing the DEP domain of EPAC and introducing mutations 
in key catalytic residues prevented endogenous localization and activity (198,199). Some 
sensors, like Epac1-camps which is used in the previous section, only contain the minimal CBD 
domain from EPAC (amino acids 157-316) and still exhibit excellent kinetic properties (EC50 
2.35 ± 0.42 μM) (88). The most recent iterations of the sensor harbor high affinity mutations and 
circularly permuted fluorophores (200,201). In general, EPAC-based sensors are the most 
prominently used for their high FRET efficiency, unimolecular structure, fast kinetics, and ease 
of localizing to various compartments (196). 
In addition to FRET sensors, genetically encoded cAMP biosensors have also been made 
from single wavelength fluorophores. Dimerization-dependent sensors from Campbell and 
colleagues consist of two fluorophores which fluoresce only when forming a heterodimer (202). 
For example, one iteration created the Red Dimerization Dependent cAMP sensor which when 
bound to cAMP exhibits a loss of fluorescence. The new Pink Flamindo sensor (Pink Fluorescent 
cAMP indicator) uses a single red fluorophore with an EPAC1 CBD inserted in the middle of the 
fluorophore by two linking regions (203). Pink Flamindo exhibits a 4.2-fold increase in 
fluorescence intensity upon cAMP binding with an affinity of 7.2 μM. Ohta et. al. took a similar 
approach but strove to obtain a higher cAMP affinity using a PKA CBD and circularly permuted 
red fluorophore (204). They created R-FlincA (Red Fluorescent indicator for cAMP) which had a 
high affinity (Kd = 0.3 μM) and expanded dynamic range (8.6-fold increase at pH 7.2) (204). 
These single wavelength, red-shifted fluorophores are advantageous because they allow multi-
color imaging whereas the range of compatible fluorophores with a FRET sensor are limited. 
Furthermore, they can be combined with optogenetic strategies that require blue-shifted 
excitation. 
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3.1.3 Localized Phosphodiesterase Activity 
Uncovering the functional effects of localized signaling can be achieved by interfering with 
cAMP accumulation. Uneven distribution of PDEs is well documented (87,205-209). 
Additionally, computational models predict the Km of the PDE isoform affects the steepness of a 
cAMP gradient (113). Lohse et. al. found cAMP proximal to PDE4A1 (Km ~2.4 μM) was <100 
nM, suggesting clusters of PDEs could form cAMP sinks but only in areas of restricted cAMP 
diffusion (~10 μm2/s) (114). Hence interfering with PDE activity or localization can help assess 
downstream signaling from compartments. Fortunately, there are a multitude of pharmacologic 
agents which target specific PDE isoforms (86,210). Genetic knockdown approaches have shown 
the role of specific isoforms in membrane and cytosolic compartmentalization (137). 
Furthermore, overexpressing dominant negatives PDE4 which displaces endogenous anchored 
PDE4 increased cAMP levels (137,211). Disrupting localization is a key strategy in studying 
compartmentalization since the endogenous activity of the protein is preserved. 
3.1.4 Signalosome Disruption 
Interfering with cAMP compartment signaling can also be achieved by disrupting the associated 
signalosome. PKA inhibition can be achieved through pharmacological (H89) and genetic 
approaches; however, it can have undesired effects since PKA is part of multiple signalosomes. 
To alter PKA localization, AKAP deletion, siRNA knockdown, and mutations of the PKA 
binding α-helix can be used to target specific PKA and AKAP isoforms and interfere with 
compartmentalization. Another approach uses interfering peptides that mimic the AKAP α-helix 
and thus prevent PKA-AKAP interactions (67). Scott and colleagues were the first to develop 
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this peptide, Ht31, which globally disrupts PKA-AKAP binding. While Ht31 is still the most 
commonly used, newer versions have been designed to interfere with PKA regulatory subunits 
RI and RII. AKAP-in silico (AKAP-IS), Super AKAP-IS, and stapled anchoring disrupters 2/3 
(STAD-2/3) all specifically interfere with PKA-RII/AKAP interactions (212-214), whereas 
PV38, RIAD, and RI-STAD-1/2 were designed to interfere with PKA-RI/AKAP interactions 
(215-217). Recently, peptide-based approaches exhibit improved cell permeability by using 
stearated peptides, TAT protein fusions, or ‘stapled’ peptides that are locked in α-helical 
formations (151,218-220). These approaches allow more specific disruption of 
compartmentalized PKA isoforms without affecting activity of the protein itself. 
Fewer methods exist for altering EPAC activity in signalosomes. Genetic knockdown 
methods have been useful for identifying EPAC function. The recently developed pharmacologic 
agent, ESI-05, specifically inhibits EPAC2 (221). EPAC1/2 inhibitors ESI-09 and HJC0197 have 
also been characterized; although, it was later found they have general protein denaturing 
properties rather than specific action on EPAC (222-224). Our lab was the first to use the N-
terminus of EPAC as a dominant negative for interfering with localization. We have further 
developed a peptide inhibitor, similar to the concept of Ht31, which interferes with EPAC-
Radixin interaction (unpublished data). 
3.1.5 Localized Adenylyl Cyclases 
To identify bone fide compartments and define their functional consequences, research would 
greatly benefit from synthetic localized cAMP production. Currently there are very few tools 
available that exhibit the temporal control needed to mimic cAMP signaling. Activation of 
specific adenylyl cyclase isoforms can be achieved using GPCR-mediated signaling; however, 
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the concomitant activation of several other pathways can mask cAMP-depended effects. Soluble 
adenylyl cyclase (sAC) variants like the sACI/II chimera (225) and truncated but catalytically 
active form of sAC (135) have been used to study the effects of membrane, cytosolic, and 
nuclear cAMP signaling. However, activation of these cyclases requires forskolin (sACI/II) or 
bicarbonate (sAC truncated) which both activate endogenous cyclases and require wash-out to 
end the stimulus. This slow temporal regulation can interfere with kinetic studies. 
Optogenetic light-activated cyclases are a powerful tool for rapid temporal regulation of 
cAMP synthesis. Photoactivated cyclases (PACs) are often derived from bacterial origins as 
cAMP signaling is a highly conserved evolutionary mechanism. For example, the first PAC 
discovered was from Euglena gracilis (euPAC). It consists of four subunits, each containing 
BLUF (sensor of blue light using flavin adenine dinucleotide)-type photoreceptor domains, two 
binding flavin adenine dinucleotides (FADs), and four catalytic domains (226). In response to 
blue light, it increases cAMP levels 80-fold (226). However, its large size (~412 kDa tetramer) 
and high dark activity makes it less than ideal for compartmentalization studies (186,227).  
The recently characterized PAC from Beggiatoa (bPAC) is gaining popularity as a blue 
light-activated cyclase capable of producing a 300-fold increase in cAMP upon stimulation 
(186,228). Compared to euPAC, bPAC is much smaller (~77 kDa dimer) and has a lower dark 
activity (33 ± 5 pmol/min/mg of protein) (186). Each monomer contains a BLUF-domain and a 
Type III adenylyl cylase. Light activation occurs within milliseconds, inducing a conformational 
shift opening the catalytic pocket of the cyclase; it returns to its dark-state quickly (τoff=12 sec) 
although residual cAMP accumulation is reported (τ=23 ± 2 sec) (186,229). Von Zastrow and 
colleagues were the first to use bPAC for spatial control over cAMP synthesis (36). By targeting 
bPAC to membrane and endosomal compartments, they discovered transcriptional differences 
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indicating endosomal cAMP signaling has functional consequences (36). Additionally, Averaimo 
et. al. targeted bPAC to lipid raft and non-raft membrane regions finding distinct physiological 
effects from raft domain signaling (148). Several have further engineered novel optogenetic 
cyclases to expand the range of activation and catalytic characteristics. Since blue light 
penetrates tissue poorly in in vivo applications (230), Gomelsky and colleagues designed an 
infrared light activated cyclase (Ilac) by fusing the phytochrome domain of Rhodobacter 
sphaeroides with an AC from Nostoc sp (231). To design a PAC with faster off-rates than bPAC, 
Sheib et. al. developed a chimeric protein using rhodopsin’s millisecond on/off-kinetics and a 
mutated guanylyl cyclase domain which converts ATP to cAMP (232). 
While optogenetic approaches are a powerful strategy that offer succinct control over 
cAMP production, it has not become a widely adopted technique. It is difficult to find 
commercially available light sources with tunable intensity and appropriate temporal regulation, 
cumbersome to mitigate external light when using typical lab techniques (ie: cell culture), and 
invasive for in vivo studies. Hochgeschwender and colleagues developed the luminopsins to 
circumvent these issues (233-235). By fusing the light-sensitive channelrhodopsin ion channel to 
Gaussia luciferase (GLuc) they created a new class of proteins with both optogenetic and 
chemical regulation of activation (233). GLuc is a small luciferase (19.9 kDa) that is activated by 
the substrate coelenterazine. GLuc emits 470 nm luminescence which overlaps with the 
excitation spectrum of channelrhodopsin, and thus it could potentially activate channelrhodopsin 
through non-radiative energy transfer. Genetic fusion of GLuc and channelrhodopsin adds and 
additional layer of control by chemical stimulation of light that bypasses the need for an external 
light source. Hochgeschwender’s group and others has further expanded the family of 
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luminopsins by using different luciferases or using halorhodopsin to create an inhibitory 
luminopsin (235,236). 
Using a similar strategy as the luminopsin protein, we have created a unique construct for 
regulating cAMP production in different subcellular compartments. We demonstrate that the 
fusion of bPAC and NanoLuciferase (nLuc) allows dual photo and chemical regulation of cAMP. 
Additionally, we have added a layer of spatial regulation using various targeting motifs to 
different subcellular compartments. The temporal and spatial flexibility of this construct make it 
widely adaptable for in vitro and in vivo applications. 
3.2 METHODS 
3.2.1 Cell Culture and Transfection 
The rat hepatoma clonal cell line HC1 (237) was grown in DMEM supplemented with 10% FBS, 
Penicillin (100 IU/L) and Streptomycin (100 mg/L). PCCL3 were grown as described in the 
previous section. Cells were grown to ~90% confluency before passaging every 2-4 days at 37°C 
in 5%CO2, 95% humidified air. For transient transfections, cells were transfected 24 hours after 
plating using Xtremegene HP (Roche) for HC1 cells, or Lipofectamine 3000 (Thermo Fischer 
Scientific) for PCCL3 cells. Cells were cultured for 24 hr and given fresh media. 
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3.2.2 Plasmid Preparation 
Humanized bPAC with myc, nLuc, and several targeting sequences were generated and 
subcloned in a pcDNA3.1+ backbone (Genescript), including bPAC-nLuc (unmodified), N-Rx-
bPAC-nLuc (amino acids 1-318 of N-Radixin), ER-bPAC-nLuc-AKDEL (endoplasmic 
reticulum, 18 amino acid BiP signal sequence + AKDEL), bPAC-nLuc-CAAX (plasma 
membrane, KRas4B-CVIM), NLS-bPAC-nLuc (nuclear localization sequence, 
PKKKRKVEDA), NES-bPAC-nLuc (nuclear export sequence LQLPPLERLTL), and 
MYR/Palm-bPAC-nLuc (myistolated/palmytolated, 17 amino acids N-terminus of Yes). All 
bPAC-nLuc sequences were subcloned into a pCDH-puro-cmyc vector (Addgene) and used to 
generate high-titer lentiviral suspensions (Cyagen Biosciences). 
3.2.3 Lentiviral Infection and Stable Cell Line Generation 
To optimize lentiviral infection conditions in PCCL3, 1x104 cells/well were seeded on a gelatin-
coated 96-well dish. The next day different concentrations of polybrene and pLV[Exp]-
EGFP:T2A:puro-EF1<mCherry lentiviral particles (1.2 TU/mL, Cyagen Biosciences) were 
mixed with complete Coon’s media and incubated with cells for 24 hr. Approximate multiplicity 
of infection (MOI) was calculated assuming cells had doubled in number. A MOI of 80 and 
concentration of 5 μg/mL polybrene was selected as the optimal infection conditions after 
imaging GFP fluorescence 48 hr after infection (Fig. 7). Stable cell lines were generated via 
puromycin selection at 1 μg/mL for 4 days and maintained under selective pressure at 0.5 μg/mL. 
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Figure 7. Lentiviral infection of PCCL3 cells.  
PCCL3 infected with high titer EGFP lentiviral particles at varying MOIs and concentrations of polybrene show 
ample expression of the construct 48 hr after infection. 
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3.2.4 Luminescence Assays 
8,000 HC1 cells were seeded in opaque 96well dishes (Corning) and transfected 24 hr later. 24 hr 
after transfection, cells were washed with phosphate-buffered saline (PBS) and incubated with 
OptiMEM lacking phenol red. Cells were stimulated with h-coelenterazine (h-CTZ, stock diluted 
in NanoFuel, NanoLight Technology) or NanoGlo® Luciferase Substrate (furimazine, Fz, 
Promega). Similarly, 5x104 cells/well of stable PCCL3 expressing bPAC-nLuc were seeded and 
stimulated 48 hr later with furimazine, Nano-Glo Endurazine Live Cell Substrate (furimazine-
4377, Fz-4377, Promega), Furimazine-5455 (Fz-5455, Promega), or NanoGlo® Live Cell 
Substrate (Furimazine-Live Cell, Fz-LC, Promega). Luminescence was quantified using a 
TeccanSpark 20M plate reader (SparkControl V1.2 software) or using a SpectraMax Paradigm 
plate reader (SoftMax Pro 6.2.2 Software) when measuring specific wavelengths. 
3.2.5 Real Time cAMP Imaging – Red Dimerization Dependent Sensor 
1.5x106 PCCL3 cells were seeded on 0.1% gelatin-coated 25 mm glass coverslips for 24 hr, 
transfected with the Red Dimerization Dependent Sensor (Montana Molecular), and given fresh 
media the next day. Cells were hormone starved for 3 hr prior to imaging in Coon’s media with 
1% FBS and lacking TSH, Insulin, and hydrocortisone (Starvation Coon’s media). Cells were 
washed twice with PBS and imaged in imaged in OptiMEM lacking phenol red on an Olympus 
IX70 microscope equipped with a Till Poly V monochromator. Images were acquired every 10 s 
with a 60x/1.4 NA oil objective, 8x8 binning and a Hamamatsu CCD camera using 570 nm 
excitation (20% monochromator intensity, 15 nm bandpass) with emission filter 620/52 nm and 
dichroic 560 nm. Cells were stimulated with light at 4.41 ± 0.301 μW/mm2 LED (450 nm) in 
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pulses varying in duration and 100 μM IBMX was added at the end to show the saturation point 
of the senor. 
3.2.6 Optogenetic Stimulation 
Cell culture and experiments were performed in a dark environment using a red safelight lamp 
(Kodak GBX-2 Safelight Filter) with a 13 W amber compact fluorescence bulb (Low Blue 
Lights, Photonic Developments LLC) to prevent light exposure from wavelengths <500 nm. 
Light activation was achieved using a custom-built, Arduino-controlled system capable of 
regulating the duration, frequency, and intensity of light exposure. The illuminating high-power 
LED (royal blue CREE XTE Tri-Star LED, LED Supply) was mounted on a stage, keeping a 
distance of 18 cm from the sample to ensure a near-homogenous spread of light (Fig. 8A). For 
experiments performed inside an incubator, samples were placed atop the stage and cells were 
illuminated from below. The stage was inverted for real-time imaging experiments, such that 
samples were illuminated from above. The light intensity used for these experiments was 4.41 ± 
0.30 μW/mm2 as measured by a laser power meter (ThorLabs PM1100D, detector S130C). The 
program allows for pulses of light from milliseconds to minutes in duration. Additionally, 
intensity range spanned from 4.41 ± 0.30 – 14.85 ± 1.00 μW/mm2 when measuring irradiance at 
18 cm distance from the LED through the bottom of a 6-well dish (Falcon, Corning) (Fig. 8B). 
The Arduino program allowed for pulses of light from milliseconds to minutes in duration. (See 
Appendix A for more details on the LED illumination system, Fig. 21-22, Table 1). 
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Figure 8. Arduino-compatible LED system and stage. 
A royal blue LED mounted on a heat sink is attached to a stage 18 cm from sample. The LED connects to the power 
source and Arduino-controlled system. The intensity and pulsatile manner of LED exposure is controlled using 
Arduino v1.6.8 software providing an irradiance range from 4-15 μW/mm2 when measured at an 18 cm distance 
through the bottom of a 6-well dish. 
3.2.7 ELISA 
1.5x105 HC1 cells were seeded in a 6-well dish, transfected, washed in PBS, lysed in 0.1 M HCl, 
and frozen at 80°C. Thawed lysates were diluted in Neutralizing Reagent to be within linear 
range and analyzed using the Monoclonal Anti-cAMP Antibody Based Direct cAMP ELISA Kit 
(non-acetylated, NewEast Biosciences). Briefly, the assay is a competitive immunoassay with 
goat-anti-mouse serum-coated plates and fixed concentrations of anti-cAMP antibody and 
cAMP-conjugated horse-radish peroxidase. Optical density was measured at 450 nm on a 
SpectraMax Paradigm reader and concentrations were calculated based on a standard curve. 
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Values were normalized to the amount of protein in lysates determined using the Pierce™ BCA 
Protein Assay Kit following manufacturer’s instructions. 
3.2.8 Immunocytochemistry 
PCCL3 cells were seeded in a 6-well dish on 25 mm glass coverslips and transfected the next 
day. 24 hr later, cells were washed with PBS, fixed for 10 min in 4% paraformaldehyde, and 
permeabilized for 10 min 0.5% Triton X-100. Cells were washed and stained with anti-myc 
(1:500, 9E10, Covance), washed with 0.05% Tween-20 in PBS, and stained with DAPI and 
Donkey anti-mouse Alexa Fluor 594 (Jackson ImmunoResearch). Images were acquired using an 
upright Olympus Fluoview FV1000 confocal imaging system with a 60x/1.45 NA oil immersion 
objective using 405 and 559 nm excitation with the appropriate filters. 
3.3 RESULTS 
3.3.1 Luminescence-Activated Cyclase Allows Dual Photo and Chemical Activation of 
cAMP Production 
To create a tool for cAMP synthesis with broad tunability, we fused Beggiatoa photoactivated 
adenylyl cyclase (bPAC) to NanoLuciferare (nLuc). bPAC is a blue-light sensitive cyclase with 
succinct on/off kinetics and high rate of synthesis (186). nLuc is a small (19 kDa) luciferase that 
emits blue-shifted luminescence in response to the luciferins furimazine (Fz) and h-
coelenterazine (h-CTZ) (238). A myc-tag was included between the two moieties to aid 
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identification and visualization. The resulting bPAC-myc-nLuc fusion protein can be activated 
by blue light or chemical stimulation of luminescence (Fig. 9A).  
To test whether the nLuc moiety retains activity in the fusion construct, we used the rat 
hepatoma cell line HC1 that has low basal levels of cAMP (8,237). Transiently transfected cells 
were stimulated with h-coelenterazine (h-CTZ) and furimazine (Fz). Cells luminesced in the blue 
light range (440-460 nm, 455 nm max) in a dose dependent manner (Fig. 9B-E). h-CTZ was used 
primarily for these experiments due to its commercial availability and ability to produce 
sufficient luminescence for activation. h-CTZ stimulated luminescence for ~1 hr (Fig. 9F), 
whereas furimazine induced luminescence was still detectable 2 hr later (Fig. 9G). New 
furimazine derivatives, endurazine (Fz-4377) and furimazine-5455 (Fz-5455), have been 
developed to provide long-lasting luminescence and lower toxicity. For example, endurazine 
contains a protecting group which requires esterase hydrolysis for activity, resulting in low but 
stable luminescence for >6 hr (Fig. 9G). Together, the different coelenterazine and furimazine 




Figure 9. Luminescent characteristics of bPAC-nLuc fusion protein. 
(A) To allow dual photo and chemical activation of cAMP production, we have created a fusion protein containing
beggiatoa photoactivated cylase (bPAC) and NanoLuciferase (nLuc). (B) Transiently transfected HC1 cells 
expressing bPAC-nLuc luminesce at a maximum of 455 nm (within the excitation range of the bPAC) when treated 
with 100 μM h-CTZ (mean ± SEM of n=4). (C) This effect occurs in a dose-dependent manner (mean ± SEM of 
n=4). (D-E) Similar luminescent properties were found with Fz which elicits higher max luminescence (mean ± 
SEM of n=4). (F) Treatment with 100 μM h-CTZ luminesces for up to 1 hr, with most of the reaction occurring in 
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the first 30 min (mean ± SD of n=4). (G) Furimazine and newly developed derivatives furimazine-live cell (Fz-LC), 
Furimazine-4377, and Furimazine-5455 elicit different luminescent kinetic signatures in lentiviral-infected stable 
PCCL3 cells expressing bPAC-nLuc (1:1000 dilutions, mean ± SD of n=4). 
 
bPAC-nLuc retained its optogenetic properties as shown in PCCL3 rat thyroid cells co-
expressing a red cAMP dimerization dependent sensor. Activation with 450 nm light occurred in 
milliseconds with cAMP levels returning to baseline levels quickly, demonstrating tight temporal 
regulation of activity with light (Fig. 10A). Furthermore, chemical stimulation of nLuc 
luminescence sufficiently activates light-sensitive bPAC. Stimulation with h-CTZ in the 
presence of IBMX induced up to >100-fold increase in cAMP accumulation in HC1 cells within 
10 minutes, as shown by cAMP ELISA analysis (Fig. 10B). Single-cell analysis of PCCL3 
expressing the red dimerization dependent sensor reveals h-CTZ stimulates sustained cAMP 
production for ~30 min (Fig. 10C-D). We found the duration and amplitude of cAMP levels 
were easily tuned by altering the light intensity and duration or the luciferin concentration and 




Figure 10. Photo and chemical stimulation activates bPAC-nLuc. 
(A) The bPAC moiety responds to 450 nm light within milliseconds (4.41 ± 0.30 μW/mm2) with longer pulses of
light inducing higher levels of cAMP. (B) h-CTZ specifically increases cAMP in HC1 cells expressing bPAC-nLuc 
in a dose dependent manner in the presence of 100 μM IBMX (mean ± SEM of n=4). ELISA analysis shows a max 
stimulation >100-fold increase from basal levels. (C-D) 25 μM h-CTZ increases cAMP within minutes using 
PCCL3 cells co-transfected with a Red cAMP Dimerization Dependent Sensor which decreases in fluorescence 
when bound to cAMP. Myc-empty vector (myc-eV) transfected cells show h-CTZ does not affect sensor readings 
(representative single cell traces shown, 100 μM IBMX and 10 μM forskolin (Fsk) show saturation of sensor).  
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3.3.2 Luminescence-Activated Cyclase Can Be Localized to Distinct Subcellular 
Compartments 
bPAC and nLuc were initially selected for their small size, resulting in a final ~60 kDa fusion 
protein. This size is at the upper limit for passively diffusing through nuclear pores (239), and the 
construct was distributed evenly throughout the cytosol and nucleus (Fig. 11). To improve spatial 
resolution of bPAC-nLuc, we targeted this construct to distinct subcellular regions using 
different targeting motifs. By modifying the N and/or C termini with targeting motifs, bPAC-
nLuc localization could be re-distributed to specific sub-cellular regions. In PCCL3 cells, 
constructs localized to the nucleus (NLS), cytosol (NES), endoplasmic reticulum (ER), Radixin-
localized submembrane domains (N-Rx), and plasma membrane (CAAX, MYR). 
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Figure 11. Luminescence-activated cyclase can be targeted to different sub-cellular regions.  
Transiently transfected PCCL3 cells stained with anti-myc (red) and DAPI (blue) demonstrate differential 
localization of pcDNA3.1+-bPAC-nLuc constructs throughout the cell (unmodified), nucleus NLS 
(PKKKRKVEDA), cytosol NES (LQLPPLERLTL), endoplasmic reticulum ER (BiP signal sequence 18aa, 
AKDEL), and plasma membrane using farnesylation CAAX (KRas4B-CVIM) and myristoylation/palmytolation (N-
term Yes 17aa). Representative images shown with 10 μm scale bar (bottom, right) with myc-empty vector (myc-
eV) negative control. 
Since lipid-based transfection of PCCL3 yields low efficiency, we subcloned the bPAC-
nLuc constructs into a pCDH-puro-myc lentiviral backbone to create lentivirus and increase the 
population of cells expressing our constructs. Stable cell lines were made from both the 
pcDNA3.1+ transfections and pCDH lentiviral infections; however, despite selective pressure, 
expression was lost after a few passages. This was true for heterogeneous and clonal populations. 
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The loss of expression may be due to selective pressure from cytotoxic effects, reduced 
proliferation, or silencing of the CMV promotor. Interestingly, HEK293 cells successfully 
formed stable lines from pcDNA3.1+ constructs and retain expression well after several 
passages. This suggests that any potential cytotoxic effects of bPAC-nLuc do not affect certain 
cell models. 
PCCL3 experiments were done using bulk populations of cells since clonal populations 
lost expression before reaching necessary quantities. In stable PCCL3 expressing lentiviral 
pCDH bPAC-nLuc, furimazine treatment stimulates luminescence immediately, suggesting that 
furimazine enters intracellular compartments like the nucleus and endoplasmic reticulum within 
a similar timeframe (Fig. 12). Furthermore, luminescence is detectable up to two hours for all 
constructs even in cells with low expression. 
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Figure 12. Stable lentiviral-infected PCCL3 expression and luminescence. 
PCCL3 infected with lentiviral bPAC-nLuc constructs were selected in puromycin to form stable cell lines. Cells 
were stained with anti-myc (green) and imaged to ensure constructs effectively localize to their appropriate 
subcellular locations. Stimulus with Furimazine induces immediate expression in all compartments, including the 
nucleus and endoplasmic reticulum lumen. Decay kinetics of furimazine-induced luminescence show the highest 
activity in the first hour with lower, but still prominent luminescence at 2 hr (mean ± SD of n=2). 
3.4 DISCUSSION 
The cAMP compartmentalization field has quickly expanded over the last two decades. A 
growing number of AKAP signalosome disruptors have been created to study compartment 
function. The field still notably lacks tools to mimic cAMP signaling with sufficient spatial and 
temporal resolution. Here, we have created a luminescence-activated cyclase that offers exquisite 
spatio-temporal control over cAMP synthesis. We show both the enzymatic activities of bPAC 
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and nLuc are preserved  in the fusion protein. h-CTZ or Fz stimulated luminescence is sufficient 
to induce a high level of cAMP production. We found cAMP production was easily tunable by 
altering the duration and intensity of light, or the duration and concentration of luciferin 
stimulation. New time-released Fz analogs are being developed to extend that duration of 
luminescence, providing multiple kinetic signatures to stimulate bPAC-nLuc. As bPAC-nLuc is 
a relatively small construct (~60 kDa), it was readily redistributed to specific subcellular location 
when modified with a localization sequence. Importantly, furimazine stimulated immediate 
luminescence in all compartments, suggesting furmazine permeability is not an issue. Hence, 
bPAC-nLuc can serve as a unique tool for mimicking location-biased cAMP signaling.  
Compared to other tools in its class, such as the sACI/II chimera (225) and truncated sAC 
(135), bPAC-nLuc does not require a chemical stimulus that could activate endogenous cyclases. 
Compared to bPAC alone (36,148), the bPAC-nLuc fusion provides more flexibility for in vitro 
studies when a light source is not available or when chronic signaling is needed. Our approach 
circumvents the individual obstacles of chemical activation and optogenetics, creating a versatile 
tool that can easily be adopted by labs entering the optogenetics field. Furthermore, it has great 
potential for in vivo applications where light sources would be highly invasive. Potential 
applications for bPAC-nLuc will be discussed in depth in the next chapter. 
Working with bPAC-nLuc requires a specific work environment. Standard fluorescent 
lighting used in most labs emits blue light at 2-3 μW/mm2 which activates bPAC. All light below 
500 nm should be blocked from the room while in use. Incidental light exposure throughout cell 
culture may induce undesired effects in cAMP-sensitive systems. We found with our best effort 
to minimize light exposure, basal levels of cAMP were relatively low in our ELISA experiments 
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and only slightly above non-transfected controls. However, in cAMP-sensitive systems like 
PCCL3 cells, a small increase in basal cAMP levels can have significant functional effects.  
When designing experiments, the stimulus must be carefully calibrated. bPAC has a very 
high maximal activity that may not correspond to endogenous cAMP signaling. Thus, tuning the 
duration and amplitude of light or chemical stimulus should be compared with endogenous 
signaling mechanisms such as GPCR-stimulated cAMP production. Using high concentrations of 
h-CTZ or furimazine can have cytotoxic and off-target effects from oxidation of the compound.
Additionally, oxidative stress and activation of endogenous flavins from blue light exposure may 
be a concern in some systems (240).  
There are several possible ways to reduce basal and maximal cAMP levels if needed. To 
lower maximum cAMP levels, we found reducing the amount of DNA during transfection lowers 
basal activity. The CMV promoter in our constructs yielded high expression, but this could be 
replaced with a low expression promoter to ensure the system does not oversaturate. 
Furthermore, the CMV promoter may have been silenced in our stable cell lines. Hence a 
different promotor or a vector which couples bPAC-nLuc and antibiotic resistance gene 
transcription would help ensure expressing cells maintain a growth advantage (e.g. pIRES, BD 
Biosciences) (241). One could also use an inducible system such as the Degradation Domain 
(DD)/Shield-1 system (Clontech) which destabilizes the protein until the ligand shield-1 is added 
(Fig. 25). Future work in our lab will include using a tetracycline-inducible promoter to prevent 
protein expression during routine cell culture. Another approach to altering bPAC-nluc basal 
activity would be to modify bPAC itself. Recently, structural characterization of bPAC identified 
the point mutation S27A which reduced basal dark activity by 40% but did not reduce maximal 
light-activated activity (242). The maximal absorbance was also red-shifted 15 nm (from 441 nm 
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to 456 nm) which should favor activation by nLuc. These variations of the bPAC-nLuc 
constructs could potentially tune expression and activity to fit the needs of the model organism. 
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4.0  POTENTIAL APPLICATIONS FOR LUMINESCENCE-ACTIVATED CYCLASE 
4.1 INTRODUCTION 
Dual photo and chemical activation of bPAC-nLuc circumnavigates the individual limitations of 
optogenetic and drug-induced cAMP production. These characteristics make bPAC-nLuc 
broadly adaptable and finely controlled for cAMP synthesis. Here we explore four potential 
applications of this tool to investigate spatial effects of cAMP signaling thyroid mitogenesis, 
mimic different temporal patterns of cAMP signaling, address the role of cAMP in a mouse 
melanoma metastasis model, and explore direct lentiviral injections of bPAC-nLuc in mouse 
thyroids. 
4.1.1 Spatial Regulation of cAMP Synthesis in Thyroid Mitogenesis 
As discussed in the previous chapters, our group identified a potential cAMP compartment 
involved in TSH-stimulated mitogenesis. We hypothesized Radixin positioned cAMP effectors 
EPAC and PKA near a site of high cAMP concentration. Using the N-terminus of Radixin, we 
show Radixin-localized sub-membrane regions exhibit increased cAMP levels immediately after 
TSH stimulus (Fig. 4). Hence, we wanted to expand our studies using N-Rx-bPAC-mCherry 
(Fig. 5) to include bPAC-nLuc constructs for expanded regulation. Our goal was to test if N-Rx 
localized cAMP production was necessary and sufficient for stimulating mitogenesis. While 
67 
transmembrane AC activation is known to promote proliferation, there is evidence that cAMP 
signaling is spatially encoded. Sustained cAMP signaling after receptor internalization suggests a 
source of cAMP production beyond the sub-membrane region can stimulate specific functions. 
Furthermore, a second layer of cAMP signaling could also come from intracellular sAC. 
Transmembrane cyclases have been shown to activate sAC through EPAC/PLC/Ca+2-mediated 
signaling (47). Since the role of sAC has not been determined in thyroid function, studying 
cAMP compartments which trigger functional effects could help identify functional sAC pools. 
Hence, we tested whether luminescence-activated cyclase could stimulate thyroid mitogenesis 
and began to test the effects of localized cAMP signaling. 
4.1.2 Temporal Regulation of cAMP in GPCR Signaling 
The dual stimulation of cAMP production by bPAC-nLuc represents two signaling modalities: 
transient pulses of cAMP production by light, and sustained cAMP production by luciferin 
stimulation. It is now well established that many GPCRs stimulate a transient peak of cAMP 
production from the plasma membrane and a following sustained phase of cAMP production 
during receptor endocytosis and redistribution in endosomes (32,33,92,94,243). Furthermore, 
multiple studies found oscillating patterns of cAMP regulate downstream functions (100-105). 
To test whether bPAC-nLuc could mimic these patterns of cAMP signaling, we transiently 
expressed bPAC-nLuc in HEK293 cells. We observed the same luminescent characteristics as 
detected in HC1 cells. h-CTZ and Fz stimulation generated blue luminescence with a maximum 
of 455 nm in a dose-dependent manner (Fig. 15A-D). High expression made luminescence 
visible to the naked eye and could be imaged using long exposures times (Fig. 15E).  
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Using HEK293 cells, we transiently expressed the high-affinity cAMP FRET-based 
sensor, YFP-EPAC-Q270E-mScarletI (H208) (Fig. 16A). Cells expressing MYR/Palm-bPAC-
nLuc generated transient spikes of cAMP accumulation in response to pulses of blue light 
between 1 and 100 sec at 4.4 μW/mm2 (Fig. 16B). Stimulation with furimazine induced a 
significantly longer signal, lasting well-beyond 30 min (Fig. 16C). Together, these two methods 
of stimulation can potentially tease out the individual effects of the transient, sustained, and 
oscillating temporal patterns of cAMP signaling. 
4.1.3 In Vivo Effects of cAMP in B16-F10 Mouse Melanoma Metastasis Model 
To test the potential applications for bPAC-nLuc in vivo, we used the B16-F10 mouse melanoma 
metastasis model to conduct a proof-of-principal experiment. This model provided easy means to 
deliver the bPAC-nLuc constructs, had a relatively short experimental time line, and provided a 
cAMP-sensitive model in an organ which would be difficult to reach with light. The model was 
developed after the B16 cell line was cultured from a spontaneous skin tumor from a C57BL/6J 
mouse (244). B16 cells are injected intravenously (i.v) into syngenic C57BL/6 mice and these 
mice develop metastatic colonies in their lungs 2-3 weeks later. By resecting these pulmonary 
tumors and growing them in culture, this process can be repeated several times to create cell 
lines with increasing metastatic potential. This was repeated 10 times to create the B16-F10 cell 
line which is highly metastatic and less genetically stable (245,246). When B16-F10 are injected 
into the tail veins of mice, they colonize the lungs forming black tumors due to high melanin 
production. This metastatic event has been shown to be regulated by cAMP, however studies are 
limited. 
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Early studies hypothesized cAMP activity promoted metastasis. Gorelik and colleagues 
found growing B16-F10-BL6, a variant of the cell line found to penetrate the bladder wall, in 
DMEM media as opposed to RPMI increases basal cAMP levels, reduces proliferation, promotes 
differentiation, and increases pulmonary tumor metastases (247). Similarly, B16-F10 cells 
treated with cAMP-elevating N-MSH ((4-norleucine-7-D-phyenlalanine)-α-melanocyte-
stimulating hormone) and sodium bicarbonate to induce differentiation exhibit increased 
metastasis (248). There is a correlation in cAMP responsiveness in cells with more metastatic 
characteristics (249-252); however, more direct studies on the role of cAMP conclude increased 
cAMP reduces metastatic potential (253-255). All reported studies using the metastasis model 
stimulate cAMP production in B16-F10 cells prior to injection with forskolin, IBMX, or GPCR 
stimulation with α-MSH. This is hypothesized to induce differentiation which negatively 
correlates with metastatic potential. However, none of these reports address the role of cAMP 
after colonizing the lung. One group tried to systemically increase cAMP by administering 
forskolin prior to injecting cells (256). They found reduced melanoma-induced platelet 
aggregation and lung colonization, but this approach lacks specificity in identifying which cell 
response is linked to the physiologic endpoint. A discrepancy remains whether cAMP inhibits or 
promotes proliferation of B16-F10 in vitro and there is little evidence of its effects in vivo 
(253,255,257). bPAC-nLuc expressing cells have the potential to test the effects of cAMP pre- 
and post-injection through luminescence-based activation. Here we injected bPAC-nLuc 
expressing B16-F10 cells and administered furimazine i.v. daily throughout the course of the 
experiment. 
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4.1.4 Direct Lentiviral Thyroid Injection with Ultrasound Guided Microinjection 
We selected another mouse model for our in vivo proof-of-concept experiments. To prevent 
artifacts from bPAC overexpression in cell lines and study cells in their native environment, we 
used ultrasound guided (USG) microinjection of bPAC-nLuc lentiviruses in mouse thyroids. 
USG microinjection is excellent to identify and inject thyroid glands in mice (258,259). 
Compared to surgical procedures it is far less invasive and leads to longer survival times (258). 
Direct lentivirus injection is ideal over other forms of genetic manipulation because it can infect 
non-dividing cells (unlike retroviruses) and requires less time to generate a model compared to 
creating transgenic mouse lines (260,261). The purpose of our study was to test whether 
luminescence-activated cyclase could stimulate thyroid cell proliferation two weeks after viral 
injections with daily furimazine treatment. Similar to previous studies in our lab administering 
goitrogen to induce cAMP-mediated proliferation in mice. Although the studies are not complete 
at the time of this dissertation, we show initial adaptation of this model for our lab. 
4.2 METHODS 
4.2.1 PCCL3 EdU Incorporation Assay 
Similar to the BrdU incorporation assays used for transiently expressing cells (Chapter 2), Edu 
incorporation assays were used on stably expressing cells for increased throughput. PCCL3 
stable cell lines expressing pCDH-bPAC-nLuc constructs were cultured as described in the 
previous section. 2x105 cells/well were seeded in a 96-well dish (Perkin Elmer, black walled, 
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clear bottom). Approximately 24 hr later, cells were hormone starved in Starvation Coon’s media 
with 5% FBS for 16 hr. Media was replaced with fresh starvation Coon’s media (5% FBS) 
containing Nano-Glo Endurazine Live Cell Substrate (Fz-4377) or DMSO. 8 hr after stimulation, 
10 μM EdU was added using a small volume and incubated an additional 16 hr. Then cells were 
washed in PBS, fixed for 10 min in 4% PFA, and permeabilized 10min in 0.5% TritonX-100. 
Cells were stained for EdU using a cocktail of 100 mM Tris buffer (pH 7.6), 4 mM CuSO4 
(Fisher Sci), 8 μM 5’-6-FAM (Lumiprobe), and 100 mM Sodium Ascorbate (Sigma) added in 
this order. Cells were incubated 30 min at room temperature, protected from light.  Finally, cells 
were washed thoroughly in PBS, stained 10 min with DAPI, and washed thoroughly in PBS 
again. Plates were imaged using a Nikon Eclipse Ti equipped with a 10x objective with help 
from Dr. Watkins. Images were analyzed as %EdU positive nuclei/total DAPI stained nuclei 
using NIS Elements Bright Spot Counting software. 
4.2.2 HEK293 Cell Culture and Luminescence 
HEK293 were grown in DMEM supplemented with 10% FBS, Penicillin (100 IU/L) and 
Streptomycin (100 mg/L). Cells were passaged at 80-90% confluence ever 2-3 days and 
transfected using Xtremegene HP (Roche) for luminescence assays. Cells were seeded in poly-
D-lysine coated opaque 96-well dishes (Corning) and transfected 24 hr later. 24 hr after
transfection, cells were washed with PBS and incubate with OptiMEM lacking phenol red. Cells 
were stimulated with h-coelenterazine (h-CTZ, stock diluted in NanoFuel, NanoLight 
Technology), NanoGlo® Luciferase Substrate (furimazine, Fz, Promega). Luminescence was 
measured and quantified as described in the previous chapter. 
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4.2.3 FRET Imaging 
The cAMP FRET sensor H208, kindly provided to us before publication by Dr. Jalink, consists 
of a YFP and mScarletI (262) fluorescent pair flanking catalytically inactive Epac1 with a high 
affinity mutation (200) (YFP-EPAC-Q270E-mScarletI, H208) and exhibits a loss in FRET signal 
upon binding cAMP. Note that the Jalink lab does not recommend this sensor for general 
experimentation due to punctate speckles forming a few days after transfection. This was 
confirmed in our hands but did not hamper our experiments which were performed 2 days after 
transfection. Cells exhibited a relatively even cytosolic distribution of the sensor in the 
experiments shown here. For further details on the construct, please contact the Jalink lab. 
HEK293 cells were seeded on poly-D-lysine coated glass coverslips and transfected using 
Lipofectamine 3000 24 hr afterwards. When using MYR/Palm-bPAC-nLuc, we used a low 
amount of DNA (100 ng MYR/Palm-bPAC-nLuc + 900 ng H208) to avoid saturation of the 
cAMP sensor. 48 hr after transfection, cells were washed and imaged in a HEPES imaging buffer 
with 137 mM NaCl, 5.4 mM KCl, 2mM CaCl2, 1 mM MgCl2, 10 mM HEPES, pH 7.3. Images 
were acquired every 30 s with a 60x/1.4 NA oil objective, 4x4 binning using 500 nm excitation 
with emission filters 510/20 (Semrock) and 620/52 and a dichroic beam splitter 468/526/596 
(BrightLine® Semrock). Data was collected using Slidebook software (Intelligent Imaging 
Innovations, Inc) and the ratio of Scarlet/YFP (donor over acceptor) fluorescence is normalized 
to maximum FRET response as determined by forskolin and IBMX stimulation. Cells were 
stimulated with 4.4 μW/mm2 LED light and 1:1000 Fz. 
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4.2.4 B16-F10 Melanoma Cell Culture 
B16-F10 cells were kindly provided by Dr. Storkus. Cells were maintained in RPMI 
supplemented with penicillin/streptomycin and 10%FBS. Cells were passaged every 2-3 days 
when ~80% confluent. Lentiviral constructs were used at a MOI of ~100 with 5 μg/mL 
polybrene (Vector Builder). Cell expression was selected with 4 days of 1.0 μg/mL puromycin 
treatment. 16 hr prior to harvesting for animal experiments, cells were maintained in puromycin-
free media to ensure maximum cell viability. 
4.2.5 Melanoma Metastasis Model 
20 female C57/BL6 mice were obtained from Jackson Laboratories and used at 13 weeks of age. 
B16-F10 expressing bPAC-nLuc and GFP were harvested in their exponential phase of growth, 
diluted in PBS, and kept on ice prior to injection. Cell culture and mouse injections were 
performed in darkness under a red lamp. 3x105 cells/200 μL/mouse were injected i.v. in the tail 
vein on ‘Day 0.’ Additionally, 3x103 cells/100 μL/mouse were injected intradermally (i.d.) in the 
lower abdomen. Extra cells were seeded to measure luminescence and cAMP (ELISA, 5x105 
cells/well) as described in the previous chapter. On Day 1-18, furimainze was injected into the 
tail veins of mice at a 1:40 dilution in 100 μL PBS (~5 μg, < 0.25 mg/kg, Stacer 2013), or PBS 
alone was injected as a control. On Day 19, mice were sacrificed and lungs and i.d. tumors were 
harvested. Prior to resection of one i.d. tumor, furimazine was injected directly into the tumor to 
test for bPAC-nLuc expression using a Nikon D7100 DSLR camera (ISO 1000-5000, exposure 1 
min). All procedures were performed according to the University of Pittsburgh Institutional 
Animal Care Committee. 
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4.2.6 Ultrasound Guided Thyroid Microinjection 
8-week-old FVB female mice were obtained from Charles River Laboratories. Mice were
anesthetized using isoflurane/oxygen, hair was removed from the throat region, and mice were 
placed on a warming stage. Using the Vevo 770 system (VisualSonics, probe 704), we identified 
the thyroid lobes which reside on each side of the trachea and just above the carotid arteries. 
High titer lentiviral particles (>109) were injected in 9 μL volumes mixed with 1 μL T800-F 
(kindly provided by Dr. Choi) using an insulin syringe (BD Biosciences, 30 G, 12.7 mm length, 
Cat #328431). Mice were imaged using an In Vivo Imaging System (IVIS Lumina, Xenogen). 
All procedures were performed according to the University of Pittsburgh Institutional Animal 
Care Committee. 
4.3 RESULTS 
4.3.1 bPAC-nLuc Stimulates Thyroid Cell Mitogenesis 
To test bPAC-nLuc functionality in thyroid cells, we transiently transfected the construct in 
PCCL3. After hormone starvation, cells were stimulated with 450 nm light over the course of 24 
hr in 500 ms pulses every 15 min at 4.4 μW/mm2. We found expression alone significantly 
increased mitogenesis even when kept in darkness (Fig. 13A), likely due to high expression in 
this model. To avoid overexpression form transient transfections, stable PCCL3 cell lines were 
tested for luminescence-stimulated activation using endurazine (Fz-4377), a Fz derivative which 
requires esterase hydrolysis for activity, resulting in low but stable luminescence for >6 hr (Fig. 
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9G). In this model the dark activity of bPAC-nLuc was not significantly different from non-
expressing PCCL3 (Fig. 13B). Light activation stimulated a clear increase in mitogenesis, 
showing our luminescence-activated cyclase is capable of inciting physiological cAMP-
dependent events. 
Figure 13. Light and luciferin-activated bPAC-nLuc stimulates mitogenesis. 
(A) Transiently transfected PCCL3 were stimulated with 4.4 μW/mm2 light for 500 ms/15 min/24 hr. Mitogenesis
was measured as the percent of BrdU positive cells out of the total number transfected cells (red = dsRed 
fluorescence or anti-myc staining) (mean ± SEM of n=3-4, each >500 cells). bPAC-nLuc expression alone 
significantly increased basal levels of mitogenesis. (B) Stable cell lines expressing bPAC-nLuc stimulated with 
long-lasting Fz-4377 (1:1000) exhibit higher levels of mitogenesis specifically. Mitogenesis was measured as the 
percent of EdU positive cells out of the total number of cells (mean ± SEM of n=5-6, each >6,000 cells). Statistical 
analysis was performed using a 2-way ANOVA with Sidak’s multiple comparisons test, * = P<0.05, ** = P<0.005. 
Although technical difficulties in maintaining bPAC-nLuc expression in PCCL3 
prevented full characterization of localized bPAC-nLuc constructs, our preliminary evidence 
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suggests cAMP synthesis exhibits location bias. Activation of nuclear, cytoplasmic, and 
myristoylated/palmitoylated bPAC-nLuc with Fz-4377 stimulated mitogenesis. Whereas 
farnesylated (CAAX), N-Rx, and luminal endoplasmic reticulum (ER) targeted bPAC-nLuc did 
not exhibit any changes in mitogenesis (Fig. 14). However, our stable cell lines lost expression 
throughout these experiments and this may have obfuscated these results. Only untargeted and 
MYR/Palm-bPAC-nLuc showed statistical significance over non-expressing cells with Fz-4377 
stimulation. Further work (i.e., controlling for expression, testing changes in drug potency) is 
needed to draw any decisive conclusions, but these results show several of the targeted bPAC-
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Figure 14. Localized bPAC-nLuc constructs stimulate proliferation. 
Stable PCCL3 cell lines expressing targeted bPAC-nLuc constructs were treated with long-lasting Fz-4377. Several 
groups exhibited increased mitogenesis however further testing is needed to confirm differences between 
compartmentalized signaling. Compared to non-expressing PCCL3 (dotted line shown to facilitate comparison), cell 
lines expressing bPAC-nLuc (unmodified) and MYR/Palm-bPAC-nLuc exhibit increased mitogenesis in the 
presence of Fz-4377 (mean ± SEM of n=3-4, 2-way ANOVA with Sidak’s multiple comparison test, * = P<0.05). 
4.3.2 In Vitro Sustained and Transient cAMP Signaling in HEK293 
To test the temporal spectrum of bPAC-nLuc activity using light or chemical stimulation, we 
examined sustained and transient cAMP production in HEK193 cells. The dual regulation of 
bPAC-nLuc can be applied to studies on persistent cAMP signaling from endosomes since it can 
mimic both phases of cAMP signaling. Transiently transfected HEK293 expressing bPAC-nLuc 
exhibit the same luminescent characteristics described in the previous chapter. h-CTZ and Fz 
stimulation emits blue luminescence with a maximum at 455 nm in a dose-dependent manner 
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(Fig. 15A-D). High expression makes luminescence visible to the naked eye and can be imaged 
using long exposures times (Fig. 15E). 
Figure 15. Luciferin-induced luminescence in HEK293. 
(A-B) Transiently transfected HEK293 expressing bPAC-nLuc were treated with h-CTZ. Cells luminesce at a 
maximum of 455 nm and respond in a dose dependent manner. (C-D) Fz treatment causes similar trends in 
luminescence. (E) Long exposure images were taken before and after 100 μM h-CTZ stimulation. 
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Using HEK293 cells, we transiently expressed the high-affinity cAMP FRET-based 
sensor, YFP-EPAC-Q270E-mScarletI (H208) (Fig. 16A). Cells expressing MYR/Palm-bPAC-
nLuc generated transient spikes of cAMP accumulation in response to pulses of blue light 
between 1 and 100 sec at 4.4 μW/mm2 (Fig. 16B). Stimulation with furimazine induced a 
significantly longer signal, lasting well-beyond 30 min (Fig. 16C). Together, these two methods 
of stimulation can potentially tease out the individual effects of the transient, sustained, and 
oscillating temporal patterns of cAMP signaling. 
Figure 16. Light and chemical activation mimic cAMP production phases in PTH receptor signaling. 
(A) Epifluorescence images of HEK293 cells expressing the cAMP sensor H208. (B) Accumulation of cytosolic
cAMP in HEK293 cells expressing MYR/Palm-bPAC-nLuc with pulses of 4.4 μW/mm2 light (mean ± SD of n=8 
cells). (C) Stimulation with 1:1000 Fz promotes sustained cAMP production well over 30 min (mean ± SD of n=4 
cells). 
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4.3.3 In Vivo Application in Mouse Melanoma Metastasis Model 
To test potential applications for bPAC-nLuc activity in vivo, we used the mouse melanoma 
metastasis model. bPAC-nLuc or GFP control lentiviruses were used to infect and create stable 
cell lines from B16-F10. We found with each subsequent passage bPAC-nLuc expression was 
reduced, suggesting either reduced proliferative rates, low cell viability, or silencing of the CMV 
promoter. To ensure the highest number of cells expressing the construct, B16-F10 were used the 
first passage after antibiotic selection. Additionally, the same cells which were prepared for 
animal injections were tested for expression and activity. GFP stable B16-F10 cell lines exhibit 
fluorescence in all cells compared to non-infected wild type (WT) cells (Fig. 17A). Expression of 
bPAC-nLuc was tested via luminescence, which we found to be very high compared to later 
passages of the cell line (Fig. 17B). Furthermore, Fz specifically stimulated cAMP production in 
the bPAC-nLuc expressing cells alone (Fig. 17C) demonstrating the cells used for the following 
experiment exhibited high levels of expression and activity. 
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Figure 17. B16-F10 stable cells used for in vivo study express GFP and bPAC-nLuc. 
cAMP activity and expression were tested in cells prepared for mouse injections. (A) GFP stable B16-F10 cells 
exhibit fluorescence compared to WT cells. (B) bPAC-nLuc expression was confirmed via luminescence where 
1:200 Fz stimulated a >900,000-fold change in luminescence. (C) B16-F10 stable cells were treated with 100 μL 
IBMX ± 1:100 Fz for 10 min and measured using an ELISA assay. Fz stimulated a >80-fold change in cAMP 
concentration specifically in bPAC-nLuc expressing cells.  
Stable B16-F10 cells were injected into syngenic C57/BL6 mice (Day 0) and treated 
daily with 100 μL of a 1:40 dilution of furimazine i.v. for Days 1-18. Mice were sacrificed on 
Day 19 and their lungs were harvested. Typically, B16-F10 cells have been reported to form 
black colonies in the lung due to their high melanin production. We found WT (not shown), 
GFP, and bPAC-nLuc cell lines formed white and black colonies. There were no significant 
differences between the number of white and black colonies in any individual group, hence the 
total number of foci should also reflect any biological differences between treatments. We found 
GFP expressing cells formed many foci regardless of treatment with PBS or Fz. Expression of 
bPAC-nLuc alone significantly reduced metastatic foci formation. Fz treatment did not further 
change this effect (Fig. 18). We suspect incidental light exposure before or during injections may 
explain why PBS treated mice still had a large effect on metastasis. 
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Figure 18. bPAC-nLuc use in the mouse melanoma metastasis model. 
C57/BL6 mice were injected with B16-F10 cells stably expression GFP or bPAC-nLuc. Mice were treated with PBS 
or 1:40 Fz (100 μL) daily. One day 19, mice were sacrificed and lungs were harvested to count the number of lung 
foci. White and black tumors show no statistical difference in individual groups. The total number of colonies was 
significantly reduced in bPAC-nLuc injected mice regardless of drug treatment (mean ± SD of n=5, 2-way ANOVA 
with Tukey’s multiple comparison test). 
In tandem, we injected cells i.d. in the lower abdomen. There were no significant 
differences in tumor volume between groups when resected on Day 19. Tumors formed in all 
groups; however, only one formed in the bPAC-nLuc + Fz group (Fig. 19A). The large variation 
in these groups may be due to the difficulty of performing these injections in low/red lighting 
conditions. We were also concerned about whether bPAC-nLuc expression was still present by 
the end of these tests since cell lines successively lost expression over time. By directly injecting 
furimazine into an i.d. tumor, we found luminescence could still be detected (Fig. 19B). This 
suggests the selective pressures in vitro differ from in vivo pressures and that bPAC-nLuc was 
still present at Day 19. 
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Figure 19. Intradermal tumor formation of bPAC-nLuc expressing B16-F10. 
C57/BL6 mice injected i.d. with GFP and bPAC-nLuc stable B16-F10 cells were treated with PBS or 1:40 Fz (100 
μL) daily. On Day 19, tumors were resected and measured. (A) Tumor volumes did not significantly differ between 
groups, however only one bPAC-nLuc + Fz mouse formed a tumor (mean ± SD of n=5, One-way ANOVA with 
Tukey’s multiple comparison test). (B) An i.d. tumor formed from bPAC-nLuc expressing B16-F10 was injected 
with Fz. A long-exposure image of the tumor shows luminescence restricted to the area of liquid.  
4.3.4 Ultrasound Guided Lentiviral Injection in Thyroid Lobes 
To examine bPAC-nLuc function in vivo we sought to inject lentiviral particles into the thyroid 
directly. Unlike our previous experiments which injected cells expressing the construct, this 
approach avoids potential light activation during injections. It also allows studies to occur in 
normal cells in their native environment and has a shorter experimental timeline than creating 
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transgenic mice. Using high resolution ultrasound imaging system, we identified FVB mouse 
thyroid glands (Fig. 20A-B). To optimize the lentiviral injection conditions, we co-injected a 
high titer GFP lentivirus with T800-F, a near-infrared halogenated fluorophore which is 
specifically absorbed into thyroid and parathyroid glands (263,264) (Fig. 20C-E).  30 min after 
injection, T800-F accumulation in the thyroid is visible (Fig. 20F). 72 hr post injection, the 
mouse thyroid still retains they fluorophore even after dissection, showing high specificity (Fig. 
20G-H). GFP expression was not detectable at this timepoint using IVIS imaging. Thyroid 




Figure 20. Ultrasound guided thyroid lobe injection. 
(A) Anesthetized mice are held on a warming platform with an ultrasound (US) probe positioned at the throat. A
microinjection needle is inserted at a 20° angle using a micromanipulator or freehand. (B) Ultrasound images at 
40mHz shows both thyroid lobes flanking the trachea. Identification is guided by the carotid arteries below the 
lobes. (C-E) For injection of T800-F and lentiviruses, the needle is inserted above the carotid artery, a 10 μL volume 
is injecting creating a ‘hole’ in the image, and after the needle is removed the injection sites are still visible but with 
relatively little tissue damage. (F) T800-F/GFP lentivirus and PBS (CTRL) injected FVB mice were imaged 30min 
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after injection on an IVIS (710-760 nm ex / 810-875 nm em) showing thyroid localization. (G-H) 72 hr later, T800-
F is still visible in the dissected thyroid. GFP fluorescence was not visible. Ultrasound image scale bars are in mm. 
4.4 DISCUSSION 
4.4.1 Luminescence-Activated Cyclase Stimulation of Thyroid Mitogenesis 
Understanding the role of cAMP in thyroid disease is clinically imperative. Several key 
observations suggest spatial and temporal regulation is necessary for normal function and 
represents an unexplored therapeutic intervention. Normal TSH stimulus of the thyroid occurs in 
a pulsatile manner while several disease models show constitutive cAMP signaling via mutation 
in the TSHR pathway promotes hyperproliferation (159-163). In intact thyroid follicles, the 
TSHR receptor has been shown to internalize upon stimulation and promote sustained cAMP 
production (32). Although, TSHR endocytosis-independent sustained cAMP signaling has been 
reported (265). Hence, teasing out the effects of transient pulses of cAMP and sustained or 
chronic cAMP signaling can positively impact clinical understanding. Furthermore, recently it 
has been shown that transmembrane ACs can indirectly activate sAC, creating a second 
mechanism for sustained cAMP signaling (47). These studies found corticotropin-releasing 
hormone receptor 1-stimulated cAMP requires sAC activity for full endocytic-dependent cAMP 
production (94). The role of transmembrane and soluble ACs in disease initiation and 
progression is poorly understood, illustrating or lack of understanding spatial cues. Our lab has 
recently found sAC is expressed in PCCL3 cells in nuclear, cytosolic, and submembrane 
compartments. Furthermore, we have found inhibition using the KH7 inhibitor blocks TSH-
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mediated mitogenesis (data not shown). To our knowledge, this is the first evidence of sAC 
function in TSH signaling. We plan to use our targeted bPAC-nLuc constructs in the future to 
determine the role of sAC and explore whether signaling is compartmentalized.  
Here we present a construct capable of testing both spatial and temporal regulation of 
cAMP signaling. In PCCL3 thyroid epithelial cells, we found bPAC-nLuc expression in stable 
cell lines induced mitogenesis when stimulated with Fz-4377 (endurazine). Fz-4377 yields very 
low levels of luminescence, however it has a very long and stable signal. Interestingly, 
overexpression of bPAC-nLuc by transient transfection lead to high levels of basal mitogenesis, 
but we still found and increase upon stimulus. These data suggest the expression and activation 
of bPAC-nLuc must be carefully tuned to each system. Furthermore, dose-responses are 
necessary for comparing between different constructs. Approaches for lowering expression and 
activation are discussed in the previous chapter. 
Further experimentation is required to confirm our findings regarding the effect of local 
cAMP production on mitogenesis. To ensure proper comparison between compartments, 
differences in expression and activity can significantly impact interpretations of the data. Yet, it 
is interesting that stimulation of bPAC-nLuc in the cytosol and nucleus triggered thyroid 
mitogenesis. While this may seem contradictory to the known membrane production of cAMP 
and our hypothesis of compartmentalization, is potentially highlights the role of sAC in thyroid 
cell proliferation. Alternatively, this may indicate the location of cAMP production is less 
important compared to other factors such as timing or concentration. Expression of bPAC-nLuc 
throughout these cell lines was significantly different, hence different maximal cAMP 
concentrations are likely. The highest expressing lines were ER, unmodified bPAC-nLuc, NES, 
and NLS, followed by CAAX, MYR, and N-Rx as determined by luminescence. Interestingly, no 
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significant increase was found from ER, CAAX, and N-Rx targeted constructs. We anticipated 
cAMP production in the endoplasmic reticulum lumen would not trigger mitogenesis since 
cAMP is membrane-impermeable (266,267). In this model, N-Rx-bPAC-nLuc did not trigger 
mitogenesis even though N-Rx-bPAC-mCherry shows a trend towards increased mitogenesis. 
Our hypothesis of a Radixin-associated cAMP compartment may be incorrect, but this could also 
be attributed to differences in expression or activity of the construct. These results must further 
be explored to verify the findings shown here. Since expression in these cell lines steadily 
decreased over time, we were not able to characterize full dose responses of light or furimazine 
to control for differences in expression and activity. For future studies, combining this approach 
with methods like flow cytometry would be a simple way to ensure even levels of expression are 
compared. 
4.4.2 In Vitro Sustained and Temporal Signaling of bPAC-nLuc 
The two modes of bPAC-nLuc activation can be manipulated to evoke multiple kinetic 
signatures for cAMP accumulation. Pulses of light can promote cAMP synthesis for seconds to 
minutes and luciferin stimulation can potentially produce cAMP for hours. Using different 
luciferin derivatives can create a broad range of activation. For example, h-CTZ luminescence 
lasts ~1 hr while the newly developed furimazine derivative provides luminescence for >6 hours. 
In HEK293, PTH-stimulated cAMP production triggers an immediate increase in cAMP 
production followed by sustained cAMP. We found this could be mimicked using bPAC-nLuc 
by stimulating with blue pulses to immediately induce high levels of cAMP or with furimazine to 
stimulate a longer, steady levels of cAMP accumulation. This approach could be useful for 
dissecting the functional effects of transient and sustained cAMP signaling using a single 
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construct. Previous approaches include inhibition of endocytosis or using biased agonists, such 
as PTHrP, which only stimulates transient cAMP signaling and does not induce receptor 
internalization (33). However, not all GPCR models have established agonists which can exploit 
that approach. Additionally, studies examining the effects of endosomal bPAC activation use a 
maximum stimulation period of 5 min to stimulate high levels of cAMP (36). Compared to 
hormone-stimulated sustained cAMP signals which can last >1 hr, using targeted bPAC alone 
mainly compares spatial regulation rather than temporal regulation. Using bPAC alone also 
means researchers are limited by the lighting equipment available. Hence, the maximum duration 
of exposure is determined by how much the lighting system can tolerate, especially when using 
high-powered LEDs where overheating can be a problem. Luminescence-based stimulation of 
bPAC circumvents these issues and stimulates a cAMP signature which more closely resembles 
physiologic sustained cAMP signaling. 
4.4.3 In Vivo Applications of bPAC-nLuc 
Luminescence activation of bPAC has several advantageous properties. In addition to the 
convenience of using chemical reagents and specificity of activation, bPAC-nLuc can be used in 
vivo to study internal organs that would be difficult to reach with light. As a proof-of-concept, 
we initially used the melanoma mouse metastasis model. In this study, we administered ~5 μg of 
furimazine daily for almost 3 weeks and did not note any changes in health. No long-term 
treatment regimens were reported prior to these experiments and our approach currently remains 
longest regimen reported. After these experiments were conducted, a group studying furimazine 
toxicity reported daily intraperitoneal administration of 20-60 μg for 1 week caused hydropic 
dystrophy of hepatocytes (20 μg having minimal damage); however, dividing the dose into 3 
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daily injections of 7 μg caused almost no liver damage (268). Thus, we believe our treatment 
regimen was within reason for minimizing toxicity. 
bPAC-nLuc expression in B16-F10 significantly reduced colony formation compared to 
GFP expressing controls. Since this also occurred in the absence of drug, we hypothesize this 
may be due to: 1) incidental light exposure during mouse injections, 2) incidental light exposure 
during routine cell culture, or 3) expression may be toxic to cells. Our in vitro cAMP ELISA 
assays suggest our cell culture conditions have minimal effects on cAMP induction and 
proliferation. Since previous studies found cAMP stimulation promoted cell differentiation, 
either high expression of bPAC-nLuc or light exposure may have triggered this response. We 
noticed over time bPAC-nLuc expressing B16-F10 cells in culture exhibit a more spread 
morphology and appear darker in color. This increased cell spreading and potentially melanin 
production are markers of differentiation in melanoma cells. More differentiated cells are 
reported to reduce lung colonization. Hence, the effect of furimazine in our study may be masked 
due to bPAC-nLuc saturating cAMP effects during or prior to injections.  
Although we minimized exposure to blue light as best as possible, most animal facilities 
are not designed to work under said conditions and the injections present a high technical hurdle. 
A better alternative for in vivo work may be direct injections of lentiviral constructs. This 
approach prevents incidental light exposure during injections and has no complications of 
altering cell characteristics prior to treatment. We are currently working to use this technique in 
our lab. We anticipate expression of bPAC-nLuc in thyroid glands will stimulate follicular cell 
mitogenesis upon treatment with furimazine. If successful, this work will serve as a proof-of-
concept for in vivo application of bPAC-nLuc. 
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4.4.4 Closing Remarks 
Over the last two decades, particularly from the beginning of this dissertation work, the number 
of articles studying cAMP compartmentalization has exploded. Since the year 2000, over 35 
unique cAMP biosensors have been developed (196). With these tools, long standing 
observations now have mechanistic explanations (14,134). Interestingly, the concept of restricted 
diffusion was used in many models even though more direct measurements of cAMP diffusion 
were only published two years ago (121,122). The cAMP compartmentalization model has 
gained broad acceptance throughout the field. Now, concepts from the cAMP 
compartmentalization model are being investigated through a clinical lens (150-152). Here we 
began to examine the role of cAMP compartmentalization in thyroid cell mitogenesis and 
develop a novel tool to dissect spatial and temporal regulation of cAMP synthesis. The 
luminescence-activated cyclase has the ability to examine the distinct roles of transmembrane 
and soluble cyclases, compare transient and sustained signaling paradigms, and potentially 
address these concepts in vivo. At this time, no other constructs available are as adaptable for 
different experimental needs, as refined in temporal control, or specific enough no minimize off-
target activation of endogenous cyclases. As the cAMP compartmentalization field expands, 
being able to artificially regulate localized cAMP signaling will be crucial to test whether this 







ARDUINO-CONTROLLED LED SYSTEM 
The LED illumination system was created keeping user-friendliness and adaptability in mind, 
such that it can be duplicated with basic working knowledge of electronics and programming. A 
photo of the complete system from the outside shows the stage that holds the LED below 
samples, and the Arduino-based control system (Fig. 8A). The stage can be placed inside a 
standard-sized incubator. A wiring diagram of the components clarifies how the system was 
designed (Fig. 21) from a parts list of components shown in Table 1 (screws, wires, etc. not 
listed). Overall cost was US $200-250 in 2015. Other parts can be substituted for the LED, 
microcontroller, touch screen, etc.; but any changes to hardware may require further changes to 
both hardware and software to ensure proper working of the system. For example, the Redboard 
(Sparkfun) was chosen as the Arduino-compatible microcontroller board. The system has not 
been tested with other microcontroller boards, but there is no foreseeable reason that other 
Arduino-compatible boards would not work with possible changes to the board connections.  
93 
Figure 21. Diagram of Arduino-controlled LED system. 
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Subsystem Description Comment Qty Vendor part# 
LED 
Cree XTE - Indus Star 
3-Up Royal-Blue 
High Power LED  
Notice the 3 LEDs are 




Wired BuckPuck - 
700mA Constant 
Current LED Driver 
with Dimming  
Outputs voltage to 
LED; takes input from 
DAC controlled by 
Arduino 
1 ledsupply.com 03023-D-E-700 
LED 
10509 Carclo Lens - 
3-Up Frosted Wide 
Spot LED Optic 
Attaches directly to 
LED to widen beam 
just enough for the 
SDS plate 
1 ledsupply.com 10509 
LED 
Arctic Silver - 
Premium Silver 
Thermal Epoxy 
For gluing the LED to 
the heat sink 1 ledsupply.com ASTA-7G 
LED 
Heat Sink – 
Wakefield 882-
100AB   
LED is mounted to 








the "project box" 1 digikey.com HM123-ND 
Box & 
Power 
PWR SUPPLY EXT 
24V 1.67A 40W; XP 
Power VEH40US24 
Main power supply 
for everything; LED 
driver requires higher 
voltage than other 
electronics 
1 digikey.com 1470-2320-ND 
Box & 
Power 
Power CABLE IEC 
TO NEMA 6'; Tripp 
Lite P006-006 
typical power cable; 
used with main power 
supply 
1 digikey.com TL415-ND 
Box & 
Power 
CON PWR JCK 2.5 X 
6.4MM HIGH CUR; 
CUI PJ-038BH 
connector on the box 





IC BUCK DC-DC 
CONVERTER MOD 
9.0V SIP3; Rohm 
BP5277-90 
Steps voltage down 
for digital electronics; 
inside the box, the 
first thing power feeds 
into 
1 digikey.com BP5277-90-ND 
Box & 
Power 
CBL USB B RCPT-





the box, so the 
connector on the 
board doesn't wear out 








similar to Arduino 
Uno, but useful 
differences 




Header Kit - R3  2 sparkfun.com PRT-11417 





Arduino ProtoShield - 
Bare PCB  1 sparkfun.com DEV-11665 
Digital 
Electronics 
Breakout Board for 
MCP4725 I2C DAC  1 sparkfun.com BOB-08736 
Digital 
Electronics 





only for display, but 
could potentially be 
used for parameter 
input instead of USB 
connection 




precise Real Time 
Clock - v2.1 
CR1632 battery not 
included! (but 
necessary to set clock)  






Wires - 40 x 3" 
(75mm) 
 1 adafruit.com 826 
Digital 
Electronics Half-size breadboard 








bundle  1 adafruit.com 153 
 
Table 1. List of Aruduino-controlled LED system components.  
 
A photo of the interior of the control box is shown (Fig. 22). Except for the LED and the 
power supply, all the electronics components were mounted inside the plastic control box, with 
holes made for the power supply connector, a USB port (used as a USB adapter for the Redboard 
USB port), and wires to the LED. The LED wires out of the box were short and had standard 
RCA-style plugs on them for quick connections.   
The Arduino program (“sketch”) used to control the LED contained detailed notes 
explaining the organization and function of the code. The segment of the code is shown here in 
text form (Fig. 23). Currently, the code is set for manual input of parameters through the Arduino 
program rather than the touchscreen included. This requires manual connection of the control 
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box to the USB port of a computer running the Arduino IDE software, and uploading the updated 
code to the Redboard. The timing paradigm for the experiment typically consists of one or more 
periodic flashes of the LED, with the train of flashes starting at a user-determined time, 
anywhere from the present (i.e., shortly after loading the new code, up to a few days from the 
present).  Each flash is of the same duration, falling in the range of 10 msec to several minutes. 
Controlling LED illumination intensity requires verification and calibration for each individual 
system to ensure the emitted light intensity of the LED is accurate and consistent as in Fig. 8B. 
We recommend for consistent intensity during experiments that only the main power supply be 
connected, rather than connecting both the power supply and computer USB which can also 




Figure 22. Arduino-controlled system. 
(A) An image of the outer box shows a LED touchscreen with the current date and time, countdown to the initial
flash, frequency, duration, and intensity of the flash. (B) An image of the inner circuitry and overall design. 
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// This program was working with:  
//       -   Arduino 1.6.8 
//       -   Sparkfun Redboard RTL-11804 
//       -   ChronoDot v2.1 
//       -   SparkFun MCP4725 I2C DAC Breakout (pn# BOB-08736) 
//       -   adafruit 1770 - 2.8" TFT LCD with Touchscreen  
 
//  Authors: Jeff M Reece, with Nyla Naim making modifications as needed. 
 
//  SUMMARY:         This program provides timing and intensity   
//  control of one or more high-power LEDs, as would be used for a 
//  typical optogenetics experiment in a research lab.   
//  The current version of this program is based on an Arduino Uno-compatible  
//  board, the Sparkfun Redboard.  Using a different type of Arduino board  
//  would require changing some of the pin connections, at the least. 
 
 
//  LED INTENSITY CONTROL: ...is managed through a 12-bit DAC which is slave  
//  to the Arduino, using the I2C protocol.  The output of the DAC is  
//  typically 0-5V, connected to a BuckPuck LED driver.  
//  This code uses a MCP4725 breakout DAC with a library taken from Adafruit. 
 
//  The user chooses a value between 0-100%, but this value is not calibrated! 
//  Explanation: The conversion from input voltage to output current in the BuckPuck 
//  happens in "reverse", meaning that OV to the BuckPuck will produce maximum 
//  current, and 5V produces zero current.  It is also not a simple straight 
//  line relationship, so that there is essentially no decrease in output  
//  current until the input reaches ~1.5V (which for the time being is called 
//  "100%"); and zero output current is essentially  
//  reached when the input hits ~4.3V (which we call "0%").   
//  Both ends are asymptotic with a pretty much inverse linear range from ~2-4V. 
 
//  In addition, the output of the LED is not linear with respect to the  
//  current that the BuckPuck provides it, with a minimum threshold current  
//  for stable output-- although it is a positive, monotonic relationship 
//  from that minimum to its maximum, rated value. 
 
//  Thus, although the output of the DAC 
//  would have 4095 addressable intensity levels, in reality not all those 
//  values are usable; and some calibration is necessary by the user. 
//  The calibration currently implemented is very, very roughly linear. 
 
 
//  TIMING:     The timing paradigm for the experiment typically consists  
//  of one or more periodic flashes of  
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//  the LED, with the train of flashes starting at a user-determined time, 
//  from the present up to a few days from the present. 
//  Each flash is of the same duration, conceivably falling in the range 
//  of 10msec to several minutes. 
//  The flashes in the train can be no faster than 1 second apart 
//  as the program is currently written, but this is an arbitrarily 
//  established safe limit given the hardware; undoubtedly the code could be 
//  be changed and the true lower limit of the hardware be determined. 
//  The upper limit is currently 32000 secs. 
//  The duration of the flash is defined in msec, but the real practical limit 
//  will most likely be determined by the hardware outside of the Arduino. 
//  The timing of the events is controlled in two ways, running in parallel. 
//  First, the generic Arduino Time library, with resolution in seconds, 
//  is used for convenience to handle the setting of the 
//  clock and interfacing with the user. 
//  For this clock functionality, it is desirable to have a true RTC 
//  (real time clock) with battery backup, 
//  so a ChronoDot v2.1 was chosen for this function, but any RTC compatible 
//  with DS1307 should work with this code.  The ChronoDot is on the same I2C 
//  interface with the DAC, but having a different address. 
//  However, for speed and resolution, 
//  calls to the internal Arduino millis function are used for the actual 
//  control of the LED timing.  The program performs bookkeeping to make sure that 
//  the time held by the clock is aligned with the millis function. 
//  PARAMETER ENTRY:  Until the touch screen on the TFT is used for input, 
//  it will be necessary to use Arduino through the USB port to manually 
//  enter timing parameters, directly in the next section of the program below, 
//  INCLUDE SECTION for libraries that are used  .... 
//  Some of these libraries must be manually downloaded, separate from the 










// ***********  MANUAL ENTRY OF PARAMETERS, UNTIL GUI IS DEVELOPED   *********** 
// **********  only change the numbers after the equals signs   ********* 
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// **********  and only in the following section  **************************** 
// If you want to set experiment parameters manually rather than through the 
// touchscreen, then set this value to true, otherwise false  
boolean SetParamsManually = true;  //  NOT YET IMPLEMENTED, SO KEEP "true" 
// if true, then doublecheck the following values before you upload 
// to the Arduino 
// *******  SET DAY AND TIME OF FIRST LED EXPOSURE  ************* 
// **********  ONLY CHANGE THE NUMBERS before the semicolon ';'  ********* 
// ***********  CHECK VALUES!   no error checking in program!!  ******** 
// *********   TRIM OFF ALL LEADING ZEROS !!!   ************************* 
const int InitExp_Year = 2016;  //  range is 2014-up 
const int InitExp_Month  =  8;  //  range is 1-12 
const int InitExp_Day  = 20;  //  range is 1-31, depending on month 
const int InitExp_Hour  = 17;  //  range is 0-23  (military style) 
const int InitExp_Minute = 0;  //  range is 0-59 
const int InitExp_Second = 0;  //  range is 0-59 
// Set how many exposures (number of cycles) : 
unsigned long TotalFlashes = 96;  
// What is the time interval from exposure to exposure (in seconds)? : 
unsigned long FlashTimeInterval = 900;  // in sec 
// Set duration of exposure in each cycle (in millisec) : 
unsigned long FlashDurationEachCycle =  500;  // in msec 
// Set the intensity of LED during each exposure (in %, 1-100) : 
unsigned long FlashIntensity = 20;  // in %, but this is uncalibrated, VERY rough 
Figure 23. Portion of Arduino code for LED illumination. 




We prepared N-Rx targeted cAMP FRET sensors from the mTurquoiseΔ-Epac(CD, ΔDEP)-
cp173Venus-Venus (H74, (198)). This FRET sensor has improved signal-noise-ratio and 
photostability compared to the Epac1-cAMPs sensor. We subcloned the N-Rx motif using 
HindIII cut sites upstream of the sensor. We found this modification effectively localized to the 
submembrane similar to N-Rx-Ep1 (Fig. 4). Using HEK293 lysates expressing H74 and N-Rx-
74, we titrated in varying amounts of cAMP (Promega) and measured the FRET ratio using a 
SpectraMax Paradigm plate reader. We found no significant differences in cAMP binding 
affinity in terms of EC50 and Hill coefficient (Fig. 24). We conducted similar studies comparing 
Ep1 and N-Rx-Ep1, however its stability in solution and lower fluorescence limited our ability to 
measure changes in FRET ratio. Still, these data suggest N-Rx is useful for targeting different 
FRET sensors and does not impact cAMP activity. 
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Figure 24. N-Rx targeting motif does not alter cAMP affinity. 
The H74 cAMP FRET sensor consists of a mTurquoise fluorophore lacking the last 11 C-terminal amino acids 
(TurqΔ) and a tandem of circularly permuted (cp173) Venus with Venus fluorophore (cpVV). The Epac1-derived 
cAMP binding motif is catalytically dead (T781A and F782A) and lacks the N-terminal DEP domain. The addition 
of the N-Rx targeting motif did not significantly alter cAMP binding affinity (EC50 or Hill coefficient) as shown by 
the normalized FRET ratio (mean ± SD of n=2). 
To reduce basal activity of bPAC-mCherry, we knew reducing the level of expression 
reduced basal proliferation by reducing the amount of DNA used in transfections (data not 
shown). Hence, we made an inducible system using the degradation domain (DD)/shield-1 
system (Clontech). By subcloning the DD sequence upstream of bPAC-mCherry, basal 
expression was undetectable by western blot analysis. The addition of 1 μM shield-1 peptide 
which binds and stabilizes the DD prevented proteasomal degradation and lead to increased 
expression within 2 hr (Fig. 25). 
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Figure 25. bPAC expression can be controlled using the DD/shield-1 inducible system. 
(A) The bPAC construct was modified to include a destabilization domain (DD) which targets a tagged protein for
proteasomal degradation. (B-C) The addition of shield-1 ligand stabilizes the protein which prevents its degradation 
and increases protein expression levels. A representative western blot analysis indicates increased bPAC expression 
after 2 hr of incubation with shield-1. 
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